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Chapter 1 Introduction 
1.1 Natural Products as Sources of Medicinal Compounds 
 Natural products have always played an important role in medicine dating back to ancient times 
when plant extracts were first used as therapeutics. Natural products have a great advantage over 
compounds derived from small molecule libraries as useful leads for  medicinal compounds as they have 
structures that have already been validated and optimized by nature to interact with the cellular 
machinery that often serves as target for drugs.1 In the realm of pharmaceuticals natural products play 
many roles including being used as medicinal agents themselves, as scaffolds for novel compounds, and 
as starting materials for semisynthetic compounds. Despite a major shift away from natural product 
discovery towards using combinatorial synthesis and library development approximately 50% of all small 
molecules approved for use as medicinal agents between the years of 2000 and 2010 were natural 
products, derived from natural products, influenced by natural products, or served as natural product 
mimics.2 Even more impressive is that between 1981 and 2010 approximately 75 % of all small 
molecules approved for use as antibiotics and 79 % of all anticancer drugs were in some way influenced 
by or mimicked a natural product.2  
 Because of the importance of natural products and natural product-like compounds in the field 
of medicine, chemists are often tasked with the development of methods that can yield the desired 
compounds. This is often made difficult by the nature of these compounds, which typically contain 
complicated heterocyclic ring systems and sometimes contain several stereo-centers. Currently there 
are several approaches commonly used to obtain these compounds.1 The oldest, and possibly the most 
obvious approach, is isolation of the natural products from their natural sources. This typically involves 
cultivating a large amount of the source species, and then using one or many of a variety of separation 
methods, that are designed to isolate the compound based on its solubility, stability, and volatility.3 
These techniques typically include various forms of extraction and chromatography, and usually have to 
be used in conjunction with one another or repeated using different conditions.3 Although this has been 
used to successfully isolate drug compounds such as penicillin G and morphine, it is often very difficult 
to achieve due to the complex mixture of compounds present in a living organism. In addition to this, 
the compound of interest may often be found at very low overall abundance in the tissues, resulting in 
low yields. This is also compounded with the fact that the isolation process usually involves the 
destruction of the source organism, which can result in major ecological impacts. An example of this was 
seen with the anticancer drug Paclitaxel (Taxol™).This compound was originally isolated from the bark of 
the pacific yew tree, requiring the destruction of the tree, at a yield of only 0.02 %, necessitating the 
destruction of 2500 trees to yield 1 kg of the drug.4 In addition to this, isolation of the natural product 
only gives access to the natural product itself, which may not be as medicinally useful as analogues of 
these compounds. A report by Newman and Cragg, demonstrates the necessity for having a convenient 
process for developing unnatural analogues to natural compounds, by demonstrating that 28 % of all 
small molecule drugs approved between 1981 and 2010 were derivatives of natural compound 
products.2  
 The other classic approach to obtaining medicinally useful compounds is through the use of total 
synthesis. This approach is useful in that it allows a chemist to create analogues of the compound which 
2 
 
may have altered or increased activity. In addition, the total synthesis of the natural compound with 
altered or removed functional groups has also been useful in elucidating the mechanism of action of 
some complex natural products.5, 6  However, due to the same complex nature of natural products, that 
give them their unique functionality, total synthesis of these compounds is no trivial matter. They often 
require several steps using a multitude of toxic reagents, resulting in low yields and large amounts of 
waste. The results of these drawbacks are typically negative environmental impacts as well prohibitively 
high costs of production at the industrial scale. Once again, Taxol is an excellent example of the 
problems associated with total synthetic approaches to obtaining natural products with the reported 
synthesis requiring more than 30 steps and giving an overall yield of 0.05%.7, 8 
 As a result of the inherent difficulties that occur when trying to isolate and synthesize complex 
natural products, a variety of techniques have been developed in order to either minimize or avoid the 
complications that arise from natural product isolation and total synthesis. These processes typically 
manipulate the natural biosynthetic machinery found in the organism that produces the compounds of 
interest. One of the most common approaches is the use of semi-synthesis, which is the process of 
extracting a natural product, and then performing chemical reactions to obtain different compounds. 
This type of approach is useful because it allows for the organism's biosynthetic machinery to build the 
complex structure, which can then be modified as desired. This approach has ultimately led to the ability 
to generate libraries of compounds based off of natural products, allowing for a bridge between library 
development and natural product research, where a gap traditionally exists.1, 9 Several interesting 
approaches to this method of drug development have been incorporated including the complexity to 
diversity approach developed by the Hergenrother group, which transforms complex natural products 
into libraries through the use of ring distortion reactions to yield compounds with diverse scaffolds.10 
Although semi-synthesis has been successful for a variety of drugs, it is limited in its ability to yield novel 
compounds, due to the fact that the researcher is often limited to performing chemistry on only 
functional groups that are easily accessible.11  This type of chemistry is also hampered by the large 
degree of functionality typically associated with natural products and the researcher is also limited to 
reactions that can be performed with a high degree of chemo-selectivity.  
 One of the solutions to the problems associated with semi-synthesis is the use of precursor 
directed biosynthesis (PDB). PDB is the process of functionalizing precursor compounds of natural 
products and incorporating these functionalized compounds into the biosynthetic pathway in the hopes 
that the compounds will be utilized to generate predictable novel unnatural analogues of the natural 
product of interest.1, 12 This means that nature might be able to create new libraries of natural products, 
if a library of precursor compounds could be developed. This is beneficial because the manipulation of 
these precursor compounds is often easier and cheaper than manipulation of the final product due to 
the precursors being structurally less complex. This approach has been commonly applied in bacterial 
systems to generate novel analogues of several natural products including hormaomycin, rapamycin, 
and pacidamycin.13-15 One of the obvious and major problems with this technique arises from the natural 
preference for the native precursor compounds over unnatural analogues, which may result in reduced 
yields of the desired unnatural analogues. 1, 12 In addition to this, the presence of the native substrate 
usually means that there will be a mixture of the natural product and its analogue, which can result in 
even more complicated purification procedures.1 One of the major solutions to these problems is the 
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use of mutasynthesis, in conjunction with PDB. This technique utilizes molecular engineering to knock 
out the genes responsible for the natural production of the precursor compounds, so there is no longer 
competition between the native substrate and the analogue. It can also be used to alter the natural 
cellular machinery to incorporate the desired unnatural functional group, preventing the need to 
synthesize the precursor compounds.1, 11, 16 These two approaches can also be utilized in conjunction 
with semi-synthesis, by incorporating an uncommon functional group that has very selective reactivity. 
For example, the addition of an alkyne or azide to the precursor compound could allow for the use of 
click-chemistry type alterations of the product. The added benefit of incorporating these types of 
unnatural functional groups is that the subsequent reactions can be performed bioorthogonally, even in 
a crude cell lysate, which can allow for alterations to be made prior to purification.16 A recent example 
of this approach involved the generation of analogues of pacidamycin, by incorporating a tryptophan 
halogenase into the proteome of a strain of Streptomyces coeruleorubidus in order introduce 7-
chlorotryptophan into the biosynthetic pathway of pacidamycin.16 The researchers were then able to 
perform Suzuki-Miyaura coupling reactions within the crude extract, and found that they obtained good 
chemo-selectivity, avoiding reaction with the other functional groups on the chlorinated pacidamycin 
analogue as well as with other compounds in the crude extract.16  
2.2 Precursor Directed Biosynthesis of Benzylisoquinoline Alkaloids 
 Several of the aforementioned techniques along with many others have been used to study 
many classes of natural products. Of particular interest is a class of natural products, termed alkaloids. 
Alkaloids are nitrogen-containing natural products derived from amino acids. Most of these compounds 
are composed of a nitrogen containing heterocycle, and typically include other heteroatoms such as 
oxygen, forming sophisticated ring structures.17 They are most commonly found in plants, although 
there have been several reports of animal and fungal alkaloids, including many of the toxic compounds 
found in amphibian skin.18 Typically these compounds are classified by the structure of the ring systems 
that they comprise, including some common ring systems  such as the ones shown in Figure 1.1.19  
 
Figure 1.1. Ring systems commonly found in alkaloids.
19
 
 These compounds display a variety of biological properties that are particularly potent to animal 
species.17 As a result of these effects on animals, they have been frequently studied as possible sources 
of pharmaceuticals, and to date have been shown to display several interesting medicinal properties. 
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These properties include, but are not limited to: anti-inflammatory (berberine), analgesic (morphine, 
codeine), stimulant (caffeine), anticancer (vinblastine), muscle relaxant (papaverine), and antibiotic 
(sanguinarine) effects.20  
 Due to the medicinal benefits of alkaloids, it would be useful to have access to a library of 
compounds derived from these compounds in order to screen these for their possible uses as medicinal 
agents. As such, a convenient method of developing analogues of these complex structures is necessary. 
Because of this, plant alkaloids present an interesting system for the testing and evaluation of precursor 
directed biosynthesis. Of particular interest in our lab are benzylisoquinoline alkaloids and those found 
in the Amaryllidaceae plant family.  
 Benzylisoquinoline alkaloids (BIAs) present an excellent system for the evaluation of PDB in 
plant systems due to their potent biological activity, and their use in a variety of drugs such as morphine 
and codeine. Some of the biological activities that have been observed include analgesic, anti-
inflammatory, and antibacterial properties.20 In addition to this, the biosynthetic pathways of many of 
these compounds have been mapped out. This is necessary for planning an efficient PDB experiment 
since the structures of the precursors must be known, in order to create useful precursor compounds. In 
the case of BIAs the biosynthesis starts with tyrosine (1), which can end up as either of two compounds, 
4-hydroxyphenylpyruvic acid or L-DOPA (Figure 1.2). These two  precursors are then converted to either 
4-hydroxyphenylacetaldehyde (3) (HPAA) or dopamine (2) respectively.21 This is followed by the first 
committed step in all benzylisoquinoline alkaloid biosyntheses, the Pictet-Spengler condensation of 
these two compounds to form the tetrahydroisoquinoline alkaloid, (S)-norcoclaurine (4), by the enzyme 
norcoclaurine synthase (NCS) (Figure 1.2). From here a series of methylations and oxidations occur to 
form the tetrahydroisoquinoline alkaloid (THIA) (S)-reticuline (5). After this point the pathways can vary 
depending on the organism, resulting in a variety of diverse and structurally interesting alkaloids such as 
morphine (Figure 1.3).21 In the plant species Berberis vulgaris, this pathway goes to produce the BIA, 
berberine (6), which is the alkaloid of interest in the present study. The pathway of berberine 
biosynthesis is continued from (S)-reticuline by a ring closure catalyzed by the berberine bridge enzyme 
(BBE), forming the alkaloid, (S)-scoulerine, yielding the  four ring protoberberine structure.21 (S)-
scoulerine is then selectively methylated at one of the phenols by the enzyme, (S)-scoulerine 9-O-
methyltransferase (STOM), to yield (S)-tetrahydrocolumbamine.21 This can then undergoes a ring closing 
reaction catalyzed by the enzyme (S)-canadine synthase (CAS), yielding (S)-canadine, which is 
subsequently oxidized by (S)-tetrahydroberberine oxidase (STOX), yielding berberine (6).21  
 In addition to the medicinal benefits of berberine, the PDB of berberine analogues also presents 
an interesting test case for future applications in other plant species as we have access to cell culture 
that yields large amounts of the alkaloid. Also because the biosynthetic pathway of berberine has been 
completely mapped out, all of the intermediates and products that would result from the PDB of 
berberine can be easily predicted. This allows for an easy analysis of crude extracts of plant culture to 
determine the success of these experiments. Once the PDB of berberine alkaloids has been evaluated, 
we hope to apply our precursor analogues to other cell species allowing for access of to analogues of 
several medicinally useful compounds including analgesic morphine, the antitussive noscapine, the 
muscle relaxant tubocurarine, the antioxidant magnoflorine, and the vasodilator papaverine, as well as 
several of the other compounds some of which are shown in Figure 1.3.21  
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Figure 1.2. The biosynthetic pathway of berberine a described by Desgagne-Penix and Facchini.21 The 
biosynthesis begins with tyrosine which differentiates into dopamine and HPAA. The red denotes the structural 
contributions by dopamine and the blue denotes the structural contributions by HPAA. The listed enzyme 
abbreviations are given by Desgagne-Penix and Facchini, and are repeated here, tyrosine/dopa decarboxylase 
(TDYC), norcoclaurine synthase (NCS), (R,S)-norcoclaurine 6-O-methyltransferase (6OMT), (S)-coclaurine-N-
methyltransferase (CNMT),  (S)-N-methylcoclaurine 3'-hydroxylase (NMCH), (S)-3'-hydroxy N-methylcoclaurine 4'-
O-methyltransferase (4'OMT), berberine bridge enzyme (BBE), (S)-scoulerine 9-O-methyltransferase (SOMT), 
canadine synthase (CAS), (S)-tetrahydroberberine oxidase (STOX).
21
  
 
Figure 1.3 Examples of the various alkaloids available from precursor directed biosynthesis of dopamine,  HPAA, 
and norcoclaurine. The red denotes the structural contributions from dopamine where as the blue denotes the 
structural contributions from HPAA. 
21
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  When trying to perform precursor directed biosynthesis, it is necessary to select a precursor 
scaffold that is: likely to make it into the biosynthetic pathway of the desired compound, unlikely to 
interfere with the primary metabolism of the host species, and will be relatively easy to synthesize in a 
cost effective manner. In the case of BIAs, there are several possible precursor compounds that are 
available for study including tyrosine, dopamine, HPAA, and norcoclaurine. It is also necessary to pick an 
alteration that will be useful for the purpose of study. In our lab, we decided to introduce halogens in 
our precursor compounds, based on several observations: their relatively small size makes them more 
likely to make it through the biosynthetic pathway, they possess unique mass spectral fragmentation 
patterns make them easy to detect using mass spectrometry (MS) analysis. Additionally, their ability to 
participate in cross coupling reactions makes them excellent functional groups for post biosynthetic 
chemo-selective modifications, allowing for potential access to libraries of unique compounds 
containing the berberine background structure.   
 Due to the several precursor compounds found in the biosynthetic pathway, there were a 
variety of precursor options available to us as routes for study. When planning for the PDB of berberine, 
we wanted to limit the possibilities based on the requirements outlined above, starting with considering 
only the compounds that were easily synthesized. This left us with the options of analogues of tyrosine, 
dopamine, HPAA, and norcoclaurine. Although it was considered, tyrosine analogues were eventually 
eliminated from consideration based on the importance of amino acids to the primary metabolism of 
plant species. The results of Runguphan et al, confirm that halogenated amino acids are unlikely to be 
suitable for PDB experiments, based on the increased selectivity of enzymes that deal with the primary 
metabolites, resulting in a bottleneck, and low yields of  the final product.22 Based on this analysis, our 
lab chose to focus on dopamine, HPAA (Figure 1.4), and norcoclaurine (Figure 1.5) as the possible 
precursor scaffolds for the development of berberine analogues. In the present study only the 
development of HPAA and norcoclaurine analogues is considered.  
 
Figure 1.4. Proposed precursor directed biosynthesis of berberine from HPAA. The HPAA analogue, and the 
structural contribution of the introduced analogue are shown in blue. X=F, Cl, Br, or I. 
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Figure 1.5. Proposed precursor directed biosynthesis of berberine analogues from norcoclaurine. The precursor 
analogue is and its structural contribution to the berberine product is shown in blue. X=F, Cl, Br, or I. 
 The synthesis of the native precursor compound HPAA has been published several times. 23, 24,25, 
26However, the synthesis of the halogenated analogues in the literature at this time. Based on these 
observations, there were many possible routes to the compounds that were considered and attempted. 
The synthesis of norcoclaurine has also been described in the literature, via a phosphate catalyzed 
Pictet-Spengler reaction between dopamine and HPAA.25 This leads to a possible strategy for the 
production of halogenated norcoclaurine analogues as well. 
 1.3 Precursor Directed Biosynthesis of Galanthamine 
 Another major class of alkaloids for the evaluation of precursor directed biosynthesis is that of 
the Amaryllidaceae plant family, in particular, the alkaloid, galanthamine. This compound is of particular 
interest as a candidate for PDB due to its acetylcholinesterase activity, and its approved use as a 
therapeutic against Alzheimer's disease and other neurodegenerative conditions.27 In addition to this, 
the currently reported syntheses of this compound require several steps that offer low degrees of 
stereoselectivity, making isolation of the compound from its natural source the most efficient route for 
commercial production.28 The biosynthesis of this compound is not as well resolved as that of berberine, 
and the incorporation of halogenated precursors may also be an interesting way to map out the 
biosynthesis due to their characteristic fragmentation pattern when analyzed by mass spectrometry, 
which may allow for the determination of some of the unknown intermediates in the biosynthetic 
pathway. It is hypothesized that the use of halogenated precursor compounds, may have some 
advantages over isotopically enriched and radioactively labeled precursors, due to the fact that some of 
the enzymes may work slower with the new analogues, possibly allowing for the buildup of intermediate 
compounds that are short lived in the natural biosynthetic pathway.   
 The known biosynthetic pathway of galanthamine (11) begins with the amino acids 
phenylalanine and tyrosine. Phenylalanine (7) is then turned into cinnamic acid via an elimination 
reaction catalyzed by the enzyme phenylalanine ammonia lyase (PAL), which is then oxidized to p-
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courmaric acid by the P450 dependent enzyme  cinnamate 4-hydroxylase (C4H) (Figure 1.6).27, 29 After 
this step, less is known about the specific enzymes that perform the individual steps, but it is known that 
p-courmaric acid undergoes a second oxidation to form caffeic acid, which is then converted to 3,4-
dihydroxybenzaldehyde (DHBA, 8) (Figure 1.6).27, 29 In parallel, tyrosine is decarboxylated to yield 
tyramine (9) by the enzyme tyrosine decarboxlase.27 These two compounds then undergo a reductive 
amination catalyzed by an unknown enzyme to form the alkaloid norbelladine (10), which is a branching 
point for the formation of several different alkaloids, some of which can be seen in Figure 1.8.27, 30 Figure 
1.7 details the currently reported biosynthesis of galanthamine which starts by the methylation of 
norbelladine to give O-methylnorbelladine. This is thought to undergo a para-ortho oxidative coupling of 
the two phenyl rings, which is spontaneously followed by a ring formation between the meta phenol at 
the 3' position of norbelladine, and the 2 position of norbelladine to give the alkaloid N-
demethylnarwedine. This is followed by a stereo specific reduction giving norgalanthamine, which is 
followed by an N-methylation to yield galanthamine (Figure 1.7).31   
 
 
Figure 1.6. The biosynthesis of norbelladine. The biosynthesis of norbelladine begins with the amino acids 
phenylalanine and tyrosine to eventually form 3,4-dihydroxybenzaldehyde (DHBA) and tyramine respectively. 
These two compounds are then condensed via a reductive amination of DHBA and tyramine to form norbelladine. 
The blue denotes the structural contribution from phenylalanine and the red show the structural contribution from 
tyrosine. The known enzymes in the biosynthetic pathway are phenylalanine ammonia lyase (PAL), cinnamate 4-
hydroxylase (C4H), and tyrosine decarboxylase.
27, 29
 Also shown is the numbering scheme used for norbelladine. 
 
Figure 1.7. The Biosynthesis of galanthamine from O-methylnorbelladine. The blue represents the structural 
contribution from phenylalanine while the red represents the structural contribution from tyrosine. 
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Figure 1.8. A sample of alkaloids accessible from norbelladine. In each case the blue represents the structural 
contribution from phenylalanine while the red denotes the structural contribution from tyrosine.
27, 30
 
 Based on what is known about the biosynthetic pathway of galanthamine, the possible 
precursor scaffolds available for use in PDB type experiments were tyrosine, phenylalanine, DHBA, 
tyramine, and norbelladine. The amino acids were not considered as possible precursors for the same 
reason as they were excluded from consideration for berberine analogues, as they are likely to interfere 
with primary metabolic pathways of the plant and may result in significant bottle necking, preventing 
formation of the desired analogues.22 Because the most direct synthetic route to norbelladine is via a 
reductive amination between DHBA and tyramine, analogues of norbelladine were not considered until 
after a convenient synthesis of either halogenated DHBA or tyramine analogues was first worked out. 
Additionally, the catecholic benzaldehyde DHBA is both oxidatively unstable in the presence of 
molecular oxygen and prone to polymerization. As such it was decided that tyramine analogues were 
the most suitable for PDB (Figure 1.9). One interesting difference between the PDB of galanthamine 
versus berberine is that there are two possible analogues that can result from the halogenated tyramine 
precursors, the structures of which can be seen in Figure 1.9. This means that the analysis of these 
products is going to be more complex. As with HPAA, there are several possible routes to the desired 3-
halotyramines, the details of which can be found in Chapter 4 of the present work.  
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Figure 1.9. Planned precursor directed biosynthesis of galanthamine analogues from halogenated tyramine 
precursors. For every tyramine analogue, there are two possible galanthamine analogues that can result. The red 
represents the structural contributions from the tyramine analogue precursor. X=F, Cl, Br, or I. 
1.4 Summary 
 Natural products have served as important sources of medicinal compounds for centuries due to 
the large variety of biological activities they possess. Because these compounds typically contain a large 
degree of functionality and many contain several stereocenters, natural products are notoriously 
difficult to synthesize often requiring several steps. This means that chemists are often tasked with the 
development of creative ways to obtain these natural compounds as well as their analogues. One of 
these approaches is a technique known as precursor directed biosynthesis. This technique involves the 
synthesis of compounds analogous to the natural precursor compounds found in the biosynthetic 
pathway of the natural product of interest.1 Once the precursor analogues are obtained, they are then 
feed to a cell line known to produce the natural product in the hope of exploiting its biosynthetic 
machinery to make unnatural analogues of the natural product.1 In the present work the synthesis of 
halogenated precursors of both benzylisoquinoline alkaloids (BIAs) and galanthamine is reported. 
Chapter 2 of this work discusses the synthesis of halogenated HPAA and norcoclaurine analogues for use 
in PDB experiments of BIAs. Chapter 3 discusses the development of an enzymatic assay for 
norcoclaurine synthase. Whereas Chapter 4 of this work includes the synthesis of halogenated tyramine 
analogues to be used in the PDB of unnatural galanthamine analogues. The development of a one-pot 
synthesis/feeding experiment of both HPAA and norcoclaurine analogues can be found in Chapter 5 of 
this work.  
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Chapter 2 HPAA and Norcoclaurine Analogues 
2.1 Introduction 
 
 When performing PDB type experiments with the intention of developing berberine analogues, 
there were several possible precursors that could be considered for study. These include tyrosine, HPAA, 
dopamine, and norcoclaurine analogues. At first glance, halogenated tyrosine analogues seem to be the 
preferable choice since mono halogenations can be achieved in high yield in just one reaction.32-34 
However, the results of Runguphan et al. suggest that halogenated amino acids are not suitable for PDB 
experiments. These results showed that chlorinated tryptophan was unsuitable for use as a substrate for 
PDB, due to a bottleneck that occurred at the tryptophan decarboxylase, resulting in low alkaloid 
product turnover.22, 35 In addition to this, tyrosine is vital to the primary metabolism of most plants, so 
any competitive inhibition of these vital pathways may also result in cellular toxicity further making 
them unsuitable for these experiments. Finally, because tyrosine is the precursor to both HPAA and 
dopamine, it would seem likely that even if there was no bottle necking effect from the halogenated 
analogues, it is likely that the final berberine products maybe a complex mixture of alkaloids that are 
halogenated at multiple sites, making the data analysis and product characterization significantly more 
complicated.  
 As a result it was decided that HPAA and norcoclaurine analogues would be more suitable for 
these types of experiments. For the target HPAA analogues several synthetic strategies were considered 
and attempted, which can be broken down into three main approaches: oxidation of 4-(2-
hydroxyethyl)phenol, Wittig olefination of 4-hydroxybenzaldehyde, and an oxidative decarboxylation of 
tyrosine. Attempts at the reduction and oxidation approaches are detailed in section 2.2 of this chapter, 
the attempted Wittig olefination can be found in section 2.3, where as the successful synthesis of the 
target halogenated HPAA analogues is detailed in section 2.4. In addition to this, a one-pot biomimetic 
synthesis of halogenated norcoclaurine analogues from the respective halogenated tyrosine analogues 
is explained in section 2.5 of this chapter.  
 
2.2 Attempts at Oxidation Chemistry 
 The first synthetic approach explored in the synthesis of the target HPAA analogues was the 
oxidation of 4-(2-hydroxyethyl)phenol (20), to the desired aldehyde oxidation state. In order to pursue 
this pathway, the alcohol had to be obtained. Although 20 is commercially available it is also expensive, 
so we hoped to be able to obtain large amounts of the alcohol cheaply through a synthetic approach 
from 4-hydroxyphenylacetic acid (12). Two different attempts at this reduction were performed 
(Scheme 2.1 and 2.2). The first approach we employed was the halogenation of 12, followed by an acid 
catalyzed esterification of the acid, and then reduction of the ester with LiAlH4 to generate the alcohol. 
The first halogenation that was attempted was an iodination of 12, using I2 in the presence of NH4OH to 
yield 3-iodo-4-hydroxyphenylacetic acid 15. Although this reaction produced the desired compound, it 
was difficult to purify the desired compound from the residual iodine and ammonia salts, often resulting 
in low yields of <50 %.  
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 However, it was hoped that the acid could be reduced in high yields to give large quantities of 
20, making this low-yield halogenation worthwhile. Previous attempts in our lab at reducing the methyl 
ester directly to the aldehyde with DIBAL-H, were low yielding, and so these were not pursued. We 
instead hoped that complete reduction to 20 with LiAlH4 would be more suitable. Although this reaction 
was successful at producing the desired tyrosol, the reaction was difficult to purify as the aluminum salt 
side products would often form gelatinous material during work up. After filtration of the gel, crude 
yields of less than 20 % were obtained. The low yields of this reaction were thought to be due to the 
desired product being trapped in this gel resulting in product loss during filtration. In addition, GC/MS 
and 1H NMR analysis indicated the presence of starting material in the crude product, necessitating 
additional purification steps and further reducing the yield. As a result of these difficulties, several 
workups were attempted, including the Fieser workup, which involves the addition of a specific quantity 
of water equal to the mass of LiAlH4, followed by and equal volume of 15 % NaOH, which is then 
followed by a volume of water equal to 3 times the mass of LiAlH4.
36 This too failed to yield a significant 
amount of the desired product. Simple quench and extraction with ethyl acetate was also attempted, 
but this approach also gave poor yields.  
  
 
 
Scheme 2.1. Suggested synthetic route to 3-halogenated-4-(2-hydroxyethyl)phenol compounds via LiAlH4 
reduction of 4-hydroxyphenylacetic acid. Conditions: i. SO2Cl2, Acetic acid (RT).
32
 ii. (NBS), ACN, Toluenesulfonic 
acid (RT).
37
 iii. I2, NH4OH, (4 
o
C).
38
 iv. cat. H2SO4, methanol, (reflux).
39
 v. LiAlH4, THF, (0
 o
C to RT).
39
  
 Although it is likely that the yields of the purification of these reactions could be increased using 
phenol protection, this was not attempted as this would add two more steps to the overall scheme, and 
we were only interesting in pursuing this approach if it proved to be cheaper than simply purchasing the 
resultant alcohol. Instead a second method for production of 20 was looked into. The method reported 
by Zhou et al. was attempted, as it allows for the protection of the phenol in situ.40 This procedure 
utilizes two equivalents of trimethyl borate to increase the reactivity of borane reductions in the 
presence of phenols without having to protect the phenol.40 The trimethyl borate presumably forms a 
complex between the electron rich alcohol, and the electron deficient boron compound, effectively 
masking the phenol proton from the reducing agent (Scheme 2.2). In addition to this, the reaction 
generates a reactive acyloxyborohydride compound , which then reacts with dimethyl sulfate to 
produce an acyloxyborane intermediate that further reacts to form a trialkoxyboroxine intermediate 
that yields the desired alcohol after undergoing acidic hydrolysis (Scheme 2.2).41, 42 Although this 
reaction went to completion when analyzed by GC/MS and 1H-NMR, the yield after purification was only 
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17.3 % making this approach more expensive than the purchase of the resultant alcohol and thus 
unsuitable for our applications. As a result of these difficulties, reductive approaches to generating 20 
analogues were abandoned. 
 
Scheme 2.2. Reaction mechanism for the reduction of 4-hydroxyphenylacetic acid (12) with trimethyl borate, 
sodium borohydride, and dimethyl sulfate.
40-42
 Trimethyl borate reacts with 11 to form the protected diboroester 
compound (41), which is then reduced by sodium borohydride giving the reactive acyloxyborohydride compound 
(42). This then reacts with dimethylsulfate to give a acyloxyborane species (43) that decomposes to the respective 
alcohol under acid hydrolysis. 
 Due to the difficulties of cheaply synthesizing 20, the compound was instead purchased from a 
commercial supplier. We hoped to generate the target analogues using the Parikh-Doering oxidation, as 
it was previously reported to successfully generated HPAA for use in enzymatic studies.23, 43  This 
strategy was hopeful as it would allow for the synthesis of the target compounds in just two steps; a 
halogenation of 20 followed by the oxidation of these halogenated alcohols to yield the desired HPAA 
analogues (Scheme 2.3) 
 
Scheme 2.3. Synthesis of HPAA and 3-halogenated HPAA analogues via the Parikh-Doering Oxidation. The values 
in parentheses indicate impure yields. Conditions: i. NaCl, oxone, acetone/water (0 
o
C to RT).
44
 ii. NaBr, oxone, 
acetone/water (0 
o
C to RT).
44
 iii I2, KI, 40 % dimethyl amine (RT).
45
 iv. Selectfluor® (RT). v. SO3-pyridine complex, 
triethylamine, DMSO (RT).
25
 The yields in parentheses represent impure yields.  
 Initial attempts at this reaction using 20 as the reactant yielded HPAA, albeit at a low yield of   
24 % after purification by column chromatography. Although the reaction yield was low, it was hoped 
that further optimization would increase the yield. Because of this, chlorinated (21), brominated (22), 
and iodinated (23) analogues of 20 were synthesized. Chlorination and bromination were achieved 
through the reaction of 20 with the respective sodium halide salt and Oxone® in acetone. This reaction 
gave good yields of 72 % for 3-chloro-4-(2-hydroxyethyl)phenol (21) and 79 % for 2-bromo-4-(2-
hydroxyethyl)phenol (22) after recrystallization from CH2Cl2. 
1H NMR analysis of the products suggests 
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that these reactions were successful. Three aromatic protons were observed for each compound, with 
one of the peaks appearing as a doublet, the second as a doublet of doublets, and the last peak as a 
singlet that shows a small degree of splitting (Figure 2.1 a and b protons, F, E, and D respectively). The 
doublet of doublet peak and the singlet that is slightly split most likely result from protons D and E, 
respectively, as labeled in Figure 2.1. This splitting is evidence that these protons undergo long distance 
coupling with one another. GC/MS analysis of these compounds was also useful in determining the 
success of the halogenations, due to the characteristic fragmentation that occurs with chlorinated and 
brominated compounds. GC/MS analysis of compound 21 displays an m/z of 172 Da, and the 
characteristic an (M+2)+ peak found in chlorinated compounds of 174 Da resulting from chlorine having 
two abundant isotopes, both of which are in agreement with the expected masses of 172.03 and 174.03 
Da (Figure 2.2). Likewise, GC/MS analysis of 22 also suggests that the reaction was successful, yielding 
the expected M+ of 216 Da and the characteristic (M+2)+ of 218 Da found in brominated compounds 
resulting from bromine having two abundant isotopes as well, both of which are in agreement with the 
expected masses of 215.98 and 217.98 Da (Figure 2.2.b). The same reaction was attempted using 
sodium iodide, but GC/MS and 1H NMR analysis showed that this reaction produced a large amount of 
the di-iodinated compound. A different approach was used where 20 was allowed to react elemental 
iodine in the presence of potassium iodide and dimethyl amine, which gave the desired 2-iodo-4-(2-
hydroxyethyl)phenol (23) with a yield of 72 %. As with compounds 21 and 22, 1H NMR analysis of the 
product displayed the expected aromatic peaks, as described above (Figure 2.1.c). GC/MS results also 
confirmed the success of the reaction showing that the product had an M+ of 264 Da, which was 
consistent with the expected mass of 264.06 Da (Figure 2.2.c). 
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Figure 2.1
1H NMR spectra for 2-halogenated-4-(2-hydroxyethyl)phenol compounds. a. 1H NMR spectrum for 2-
chloro-4-(2-hydroxyethyl)phenol. b 
1
H NMR spectrum for 2-bromo-4-(2-hydroxyethyl)phenol. c. 
1
H NMR spectrum 
for 2-iodo-4-(2-hydroxyethyl)phenol. In each case, the labeled protons represent the respectively labeled peaks. In 
Figure 2.3a and 2.3b, the solvent is acetone-D6, which corresponds to the peaks shown at 2.07 ppm, while the peak 
at 2.95 ppm most likely corresponds to water. In Figure 2.4.c the solvent is CDCl3, corresponding to the peak at 
7.29 ppm, while the peak at 1.56 ppm most likely corresponds to water. The peak trailing off of the water peak at 
1.66 ppm may correspond to proton HA, as labeled on the spectra, but is not integrated due to the overlap with the 
water peak. 
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Figure 2.2. GC/MS spectra for 2-halogenated-4-(2-hydroxyethyl)phenol compounds . a. GC/MS spectrum for 2-
chloro-4-(2-hydroxyethyl)phenol. MS analysis of this compound yielded a M
+
 of 172 Da and a (M+2)
+
 of 174 Da 
consistent with the expected masses of 172.03 and 174.03 Da. b. GC/MS Spectrum for 2-bromo-4-(2-
hydroxyethyl)phenol.MS analysis of this compound revealed a M
+
 of 216 Da and an (M+2)
+
 of 218 Da, agreeing 
with the expected values of 215.98 and 217.98 Da. c GC/MS spectra for 2-iodo-4-(2-hydroxyethyl)phenol. GC/MS 
analysis of this compound yielded a M
+
 of 264, which agrees with the expected value of 264.06 In Figures 2.5.a and 
b the insert serves to emphasize the (M+2)
+
 peaks resulting from the chlorine and bromine ions present in the 
molecule.   
  In addition to this, the synthesis of 2-fluoro-4-(2hydroxyethyl)phenol (24) was also attempted, 
by reacting 20 with 1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) 
(Selectfluor®). GC/MS analysis of the products however, showed two different peaks with a mass 
consistent with monofluorinated (2-hydroxyethyl)phenol products, suggesting that fluorination was 
occurring in two different locations on the benzene rings.  GC/MS analysis also revealed a peak 
consistent with a di-fluorinated (2-hydroxyethyl)phenol product, suggesting that this reagent was over 
fluorinating the compound as well. Finally 19F NMR analysis of the products displayed several peaks, 
confirming that this reaction was not selective for the desired product. HPLC analysis also resulted in a 
chromatogram showing several peaks that were very close in retention time, suggesting that the side 
products would not be easily resolved by chromatography. As a result it was decided that this method 
would not be useful for synthesizing the desired fluorinated compound. As such no further attempts at 
fluorination were performed.  
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 Although the halogenation reactions on tyrosol proceeded with little difficulty, the subsequent 
oxidation was still low yielding giving several side products which can be seen in Figure 2.3. This figure 
shows an HPLC chromatogram of a typical Parikh-Doering oxidation of 20, using two equivalents of 
sulfur trioxide pyridine, two equivalents of triethyl amine, and DMSO, depicting the undesired side 
products.43 The presence of these side products with such close retention times, meant that a difficult 
and low yielding column was necessary for the purification of these products was necessary.  
 
Figure 2.3. Reverse phase HPLC chromatogram of a typical Parikh Doering Oxidation of Tyrosol. This 
chromatogram was generated by plotting the intensity of the maximum absorbance at each time. As expected, 
pyridine, DMSO, and HPAA are present along with several other unknown side products.  
 This oxidation was repeated on compounds 21, 22, and 23 as well using. Column 
chromatography of the products resulted in a large amount of product loss with yield of 35 %, 6.2 %, and 
26 % for 3-chloro-4-hydroxyphenylacetaldehyde (25), 3-bromo-4-hydroxyphenylacetaldehyde (26), and 
3-iodo-4-hydroxyphenylacetaldehyde (27) respectively. In addition to this, the products still contained 
impurities, as seen in 1H NMR spectra (Figure 2.4), which show several undesired peaks in each of the 
spectra. 
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Figure 2.4. 
1
H NMR spectra for 3-halogenated-4-hydroxyphenylacetaldehyde analogues synthesized using the 
Parikh-Doering Oxidation. a. 
1
H NMR spectrum for 4-hydroxyphenylacetaldehyde synthesized using the Parikh-
Doering Oxidation of tyrosol after column purification. b. 
1
H NMR spectrum for 3-chloro-4-
hydroxyphenylacetaldehyde synthesized using the Parikh-Doering Oxidation of 3-chloro-tyrosol after column 
purification. c. 
1
H NMR spectrum for 3-bromo-4-hydroxyphenylacetaldehyde synthesized using the Parikh-Doering 
Oxidation of 3-bromo-tyrosol after column purification. d. 
1
H NMR spectrum for 3-iodo-4-
hydroxyphenylacetaldehyde synthesized using the Parikh-Doering Oxidation of 3-iodotyrosol after column 
purification. In each spectrum the peaks labeled with a letter correspond to the respectively labeled peaks in the 
accompanying image, whereas the unidentified impurities are circled in black. In each case the solvent is CDCl3, 
corresponding to the peak at 7.29 ppm. 
  To improve yields, several methods to optimize this reaction were attempted. The first attempt 
was the addition of pyridine to the reaction mixture which has been suggested to eliminate side 
products.46 Pyridine sulfuric acid, a common impurity found in pyridine sulfur trioxide, can react to form 
side products, and the addition of excess pyridine can quench this reactive species through the 
formation of the less reactive di-pyridine sulfuric acid.46 We hoped that this modification would increase 
yields of HPAA and its analogues, however the yields or purity were not significantly altered. This 
suggested that the side product formation was not the result of the pyridine sulfuric acid side product. 
As a result of this, the reaction was then performed at lower dilution of reagents in CH2Cl2 and a reduced 
temperature of 0 oC. This too, however, did not result in higher quality product. Because of the low yield 
associated with this synthesis, this approach to the desired compounds was no longer pursued. 
  .  
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2.3 Attempts at Wittig Olefination 
 Because of the many difficulties surrounding oxidation of 20, the second strategy of Wittig 
transformation of 4-hydroxybenzaldehyde (28) was pursued. This approach utilized the commercially 
available Wittig reagent, methoxymethyltriphenylphosphonium chloride, to transform the benzaldehyde 
into a methoxyvinyl phenol, which can then tautomerize in the presence of strong acid. This approach 
was previously used by Seganish and DeShong to transform a benzaldehyde into the corresponding 
phenyl acetaldehyde, and so we hoped that it would be suitable for the synthesis of the desired HPAA 
analogues.47 The first step for this route required the synthesis of halogenated 4-methoxybenzaldehyde 
precursors. These were synthesized from 28 in with good yields (Scheme 2.4). 3-chloro-4-
hydroxybenzaldehyde (29) was obtained from the reaction of SO2Cl2 with 28 in acetic acid with a 
satisfactory yield of 61%. Although the yield was not less than desired, the product of this reaction 
precipitated from solution after forming. This prevented di-halogenation and also made for easy 
purification by filtration followed by recrystallization from water, making this reaction easily scalable. 3-
chloro-4-methoxybenzaldehyde (31)  was then synthesized through a SN2 type reaction between 28 and 
methyl iodide with a good yield of 79 % after extraction and filtration through a silica plug. Likewise, 3-
bromo-4-methoxybenzalehyde (32) was synthesized from 28 in two steps. In this case the protocol 
reported by Bovosombat et al. for the synthesis of mono-halogenated phenols was followed.37 This 
protocol called for the use of p-toluenesulfonic acid (TsOH) to prevent over halogenation of the benzene 
ring. Over halogenation was prevented through the formation of an intermolecular hydrogen bond 
between the sulfonic acid and the phenol, which prevents di-halogenation by blocking the other 
available site (Figure 2.5).37 This reaction worked well producing 3-bromo-4-hydroxybenzadehyde (30) 
with an 86 % yield after extraction and recrystallization from water. As with the chlorinated analogue, 
the brominated compound was also easily methylated through an SN2 reaction with iodomethane which 
resulted in an 81 % yield of 32 after column chromatography.  
 
Scheme 2.4. Synthesis of halogenated benzaldehydes. The yields of each reaction are reported below each of the 
respective compounds. Conditions: i. SO2Cl2, acetic acid (RT). ii. N-bromosuccinimide, acetonitrile (RT). iii. methyl 
iodide, CH2Cl2, 2 M NaOH, tetrabutylammoniumhydrogensulfate (RT).  
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Figure 2.5. Schematic indicating the selectivity for mono halogenation when using NBS and TsOH. The selectivity 
of this reaction is likely due to the formation of an intermolecular hydrogen bond between TsOH and the phenol, 
which prevents halogenation of one of the ortho positions by physically blocking that site.
37
 
 In order to demonstrate the viability of the Wittig reaction, the commercially available 4-
methoxybenzaldehyde was used as a surrogate for the halogenated precursors (Scheme 2.5). The typical 
procedure for this reaction was to react methoxymethyltriphenylphosphonium chloride with two 
equivalents of base to form the reactive phosphonium ylide species, and then introduce the aldehyde to 
the reaction mixture and reflux to produce the methoxyvinyl anisole compound (36) (Scheme 2.5). The 
reaction however, did not proceed as smoothly as planned, as analysis by GC/MS showed no peaks with 
the expected m/z of 164 Da. An unknown peak with an m/z of 216 Da was instead observed (Figure 2.6). 
Attempts to rationalize this peak were made, but were ultimately unsuccessful since the expected 
products m/z would only be 164 and the side product, triphenylphosphine oxide, has an expected m/z of 
278 Da, and would not be expected to fragment into a species with the observed mass. In a further 
attempt to rationalize this peak, a GC/MS sample of the Wittig reagent was performed to ensure that 
this was not a contaminant present in the reagent. This sample showed only one peak with an m/z of 
262 Da, which is consistent with triphenylphosphine, but not methoxymethyltriphenylphosphonium 
chloride, which is expected to have an m/z of 308 Da. 1H NMR sample confirmed that the reagent was 
good, resulting in the expected fifteen aromatic protons, three methoxy protons, and two methylene 
protons.  
 
Scheme 2.5. Suggested synthesis of HPAA via Wittig olefination of 4-hydroxybenzaldehyde and related 
compounds. Conditions i. methoxymethyltriphenylphosphonium chloride, NaH, THF (RT).
48
 ii. HCl (reflux).
48
 iii. 
BBr3, CH2Cl2 (-78 
o
C to RT).
49
 
 With all of this evidence in hand it became clear that the problem was with the reaction itself 
and so the reaction was attempted using several other conditions, which are summed up in Table 2.1. In 
total, the reaction was performed using 5 different bases, three different solvents, several different 
temperature conditions and with three different aldehydes. In each case GC/MS analysis consistently 
showed the same side product of 216 Da and no evidence of the desired compound. Additionally, 1H 
NMR analysis suggested that the resulting product was a mixture of several compounds that were not 
characterized.  Because the 216 peak was consistent amongst all of the different conditions even when 
using different aldehydes, it seems likely that this peak is comes from the Wittig reagent, and not the 
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aldehyde, suggesting that the Wittig reagent was decomposing rather than reacting with the aldehyde 
to produce the desired compound. To test this theory, methoxymethyltriphenylphosphonium chloride 
was reacted in the presence of base without adding any aldehyde, and a GC/MS sample was taken 
(Figure 2.6). Once again the product with m/z of 216 was observed confirming that this product is a 
degradation product of the Wittig reagent suggesting that this approach would not be useful in 
synthesizing the desired HPAA analogues.  
Table 2.1. Conditions used in the attempt to optimize the Wittig reaction.  
Aldehydes Solvents Bases Temperatures 
28 THF NaH 0 oC 
  LiOH  
33 Diethyl ether NaOH Room temperature 
  Sodium methoxide  
34 Methanol Potassium t-butoxide 
Reflux temperature of 
each solvent 
 
 
Figure 2.6. GC/MS chromatogram and spectra demonstrating the formation of a 
methoxymethyltriphenylphosphonium chloride degradation product observed during the attempted Wittig 
transformation of 4-methoxybenzaldehyde. The unknown side product appears with an m/z of 216, which is not 
consistent with the molecular weight of any expected intermediate, product, or side product of the Wittig 
transformation, and it was ultimately discovered to be a product of the degradation of our Wittig reagent. 
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2.5 Successful Synthesis of HPAA analogues 
 Next, we attempted to generate HPAA by oxidative decarboxylation of the amino acid tyrosine 
in the presence of NaOCl under buffered conditions at pH 7. This approach was of particular interest 
because it was also used to make HPAA for use in enzymatic studies of norcoclaurine synthase. In 
addition to this, it also benefited from the use of much more environmentally benign reagents rather 
than using harsh and toxic compounds such as pyridine. With this in mind a new synthetic strategy that 
involved the halogenation of tyrosine followed by this oxidative decarboxylation was envisioned and 
pursued (Scheme 2.6).  
 
Scheme 2.6. Synthetic strategy for the synthesis of HPAA analogues from the oxidative decarboxylation of 
halogenated tyrosines. Conditions: i. SO2Cl2 acetic acid (RT). ii. HBr, Br2, acetic acid (RT). iii. I2, NH4OH. iv. 
Selectfluor® methanol, (RT). v. 1 equivalent NaOCl, phosphate buffer pH 7.  
 GC/MS and 1H NMR analysis of the initial attempts at this approach show that the reaction was 
unsuccessful, resulting in a large quantity of a side product with an m/z of 133 Da, which was 
determined to be an over-oxidized side product, 4-hydroxybenzylcyanide. This was confirmed by 
isolation of the product by an ethyl acetate extraction, and 1H NMR analysis of the product, which can 
be seen in Figure 2.7.  
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Figure 2.7. 
1
H NMR Spectrum for the observed nitrile side product, 4-hydroxybenzylcyanide. In each case the 
lettered peaks correspond to the lettered protons in the chemical structure. 
  This observation was problematic as the major product of this reaction was the nitrile rather 
than the desired aldehyde. The initial protocol suggested a cold addition of 1 equivalent of a household 
bleach solution to a solution of 10 mM tyrosine in 20 mM phosphate buffer at pH 7.26, 50 After several 
attempts at this procedure, it was proposed that the household bleach solution might be a problem due 
to the different additives found in these solutions such as sodium carbonate, sodium hydroxide, and 
sodium polyacrylate.51 A solution of 10-15 % reagent grade sodium hypochlorite was used instead. 
Initially, the presence of the nitrile compound was still observed. The nitrile disappeared, however, 
when less NaOCl was added, suggesting this reaction is sensitive to the amount of oxidant added. 
Therefore, the sodium hypochlorite solution was titrated to determine the exact concentration of the 
10-15% solution. This was done through the use of an iodimetric titration method. By this method I– is 
oxidized to I2 by OCl
–. This I2 then reacts with excess I
– in solution to form I3
– (Eq. 2.1).52 This solution can 
then be titrated against a standardized solution of sodium thiosulfate, which works to reduce the 
triiodide anion back to I– (Eq. 2.2).52  
                    
      
(2.1) 
   
       
            
   (2.2) 
 
 Titration revealed the concentration of the commercial solution to be 9.16 % NaOCl by weight 
(1.48 M), meaning that 673 µL of this solution contained 1 mmol of NaOCl. In practice, it was found that 
700 µL of this solution was sufficient to transform 1 mmol of tyrosine into HPAA without producing the 
nitrile side product. Although this revelation greatly decreased the amount of the nitrile side product, 
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following the reaction by HPLC revealed that there were still traces of other unidentified side products 
produced when the reaction was run at 10 mM tyrosine. These side products however, were not 
observed when the reaction was performed at 1 mM tyrosine. This suggested that the concentration of 
tyrosine also affected the purity of the final product, and as such a tyrosine concentration study was 
performed to determine the maximum concentration that would eliminate side products. Figure 2.8 
shows the results at six different concentrations of tyrosine (1, 2, 3, 4, 5, and 8 mM). In each case a 0.1 
mM solution of NaOCl was added dropwise at a rate of 1 mL/min via syringe pump in a 37 oC warm room 
to a tyrosine solution in pH 7 phosphate buffer solution. The reaction was then allowed to stir at 37 oC 
for 1.5 to 2 hours. The undiluted reaction mixture was then analyzed by reverse phase HPLC. From this 
experiment, it was determined that 4 mM was the highest concentration that would deliver minimal 
side products, since it was observed that concentrations of 5 and 8 mM yielded several different peaks 
other than the desired compound (Figure 2.8). Based on these results, all future results were performed 
at a maximum concentration of 4 mM tyrosine.  
 
Figure 2.8. HPLC chromatograms for the optimization of the oxidative decarboxylation of tyrosine. a. 1 mM 
tyrosine. b. 2 mM tyrosine. c. 3 mM tyrosine d. 4 mM tyrosine. e. 5 mM tyrosine. f. 8 mM tyrosine. In all cases the 
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starting material, tyrosine, and product, HPAA are labeled, and unknown side products are pointed out for the 5 
and 8 mM reaction. In each case the chromatograms were generated by plotting the intensity of the maximum 
absorbance at each time. 
 Finally, we examined the dependence of the rate of this reaction on buffer catalysis. As before, 
one equivalent of NaOCl was added dropwise to tyrosine, but with a series of concentrations of pH 7 
phosphate buffer (0-30 mM).  Time points for each of these reactions were collected approximately 
every ten minutes, by quenching a sample of the reaction with DMSO, and then analyzing the reaction 
via HPLC. The integrated areas of the absorbance peaks at 275 nm of tyrosine and HPAA were integrated 
and fit to an exponential function in order to determine the observed rate constants of tyrosine 
disappearance and HPAA appearance. Figure 2.9.a displays what a sample of data from this study looked 
like, showing the disappearance of tyrosine and the appearance of the HPAA products. In addition to 
this, the appearance and disappearance of an undetermined intermediate is also seen. Figure 2.9.b and 
c display the disappearance of tyrosine and the appearance of HPAA at all of the tested concentrations 
of phosphate.  
 
Figure 2.9. Sample data for the kinetic study of the oxidative decarboxylation of tyrosine. a. Sample data for the 
reaction at 2 mM tyrosine. The diamonds represent tyrosine, triangles the intermediate, and circles HPAA. b. Plots 
of tyrosine disappearance. c. Plot of HPAA appearance. 
 The resulting rate constants were then plotted against the respective concentrations of 
phosphate buffer to determine the phosphate dependence. Figure 2.10.a  shows the observed rate of 
tyrosine disappearance as a function of phosphate concentration. From this plot, there appears to be a 
linear dependence of the rate constant of the concentration of the phosphate buffer, however three 
points ([HPO4
2-= 0,1, and 30 mM) do not follow the trend line. The low concentrations of phosphate may 
not fall along this line due to the fact that at these concentrations the reaction may not be buffered, and 
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the pH may change during the course of the reaction as NaOCl is added and CO2 is produced. The point 
at 30 mM may suggest that the increase in the rate constant might level off after 20 mM phosphate 
since the rates at 20 and 30 mM are approximately equal within their experimental error. Although this 
data needs to be reproduced for greater confidence, it does suggest that there is some phosphate 
dependence for the first step of this reaction. Figure 2.10.b however, shows the observed rate constant 
of HPAA appearance as a function of phosphate buffer. The points for this plot appear to be randomly 
scattered suggesting that there is no dependence on phosphate concentration for the rate constant of 
HPAA appearance (the second step of the reaction), thus the overall rate constant of this reaction is 
independent of the buffer concentration used. These results also suggest that the first step of this 
reaction occurs faster than the subsequent steps, since the rate of product appearance does not agree 
with the rates of tyrosine disappearance. If this first step, were the slowest step then we would expect 
this rate to be equal to the rate of product appearance. Since these two rates are unequal, however, it 
appears that a step following the decomposition of tyrosine is slower and affects the rate of HPAA 
appearance. Currently these experiments are being repeated to confirm both of these observations, by 
using an alternative method that removes the quench procedure by injecting a sample of the reaction 
directly into the HPLC at regular intervals. This should confirm that the observed trends realistically 
represent the kinetics of the reaction, and that they are not influenced by the quenching procedure.  
 
Figure 2.10. Results for the kinetic study of the oxidative decarboxylation of tyrosine. a. Observed rate constant 
dependence of tyrosine decay as a function of phosphate buffer.  The points in red correspond to 0, 1, and 30 mM 
phosphate. Linear regression results of the points between 2 and 25 mM give a relationship of      
                                                 . b. Observed rate constant dependence of 
HPAA appearance as a function of phosphate concentration. In both cases the rate constants were determined by 
fitting the respective curves in Figure 2.9 to an exponential function. The error bars are the error as calculated by 
the fitting program. 
 With the oxidative decarboxylation procedure optimized to yield a single product, a work up and 
purification procedure needed to be optimized as well. It was hoped that simple extraction would be 
sufficient to yield pure product since it was expected that the zwitterionic tyrosine would not be soluble 
in the extraction solvent. Because of this, an ethyl acetate extraction was performed, which yielded the 
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compound without any tyrosine impurity. However, NMR analysis of the isolated product showed that 
the compound decomposed at room temperature during the rotary evaporation process. Figure 2.11 
shows 1H NMR spectra of 3-chloroHPAA, before and after rotary evaporation to remove the observed 
ethyl acetate. These spectra show the appearance of several new peaks, which were not present in the 
initial spectrum, suggesting that the compound was decomposing at room temperature. The 
observation of  this decomposition is in agreement with other reports that the aldehyde is not stable in 
solution, with reported half-lives of < 1hr.53 The instability of the product suggested that the product 
needs to be concentrated quickly and at lower temperature than the heated bath of the rotary 
evaporator. This was achieved by simply changing the extraction solvent from ethyl acetate to 
dichloromethane, which has a significantly lower boiling point than ethyl acetate, allowing the solvent to 
be removed under vacuum while cooling with an ice bath, allowing for greater stabilization of the 
product.   
 
Figure 2.11. 
1
H NMR evidence of the instability of halogenated HPAA analogues. a. 
1
H NMR spectrum for 3-
chloroHPAA, with ethyl acetate. b. 
1
H NMR spectrum for 3-chloroHPAA after one more hour under vacuum at 
room temperature. The circles show the new peaks that appeared after being under reduced pressure to remove 
ethyl acetate impurity. In addition to these new impurities, some of the ethyl acetate still remains. In both cases 
the peak at 7.29 ppm corresponds to the CDCl3 solvent peak, while the peak at 1.56 ppm is most likely due to 
water. 
 With both the reaction and isolation optimized for HPAA, halogenated analogues of tyrosine 
were prepared for the purpose of synthesizing halogenated HPAA analogues. Chlorination of tyrosine 
with SO2Cl2  was straightforward as the product precipitated from the solution after halogenation 
preventing di-halogenation from occurring. This reaction gave a yield of 66 % of compound 41 as the 
hydrochloride salt after filtration and recrystallization from HCl. Similarly the bromination by Br2 and HBr 
was also straightforward as the product also precipitated from the solution after halogenation 
preventing the di-halogenation from occurring, yielding 70 % of compound 42 as the hydrochloride salt 
after filtration and recrystallization from HCl. Iodination of tyrosine by I2 in NH4OH, was more difficult, 
yielding only 30 % of 43. This low yield was most likely a result of the fact that the reaction requires the 
use of a difficult precipitation procedure from water by acidification and removal of the water under 
reduced pressure until only 10 % remained. It may have been likely that some of the product remained 
soluble in the remaining aqueous solution, resulting in the lower yield. However, retaining some water 
was necessary to remove the iodine and ammonium salts from the solution. As with the halogenated 
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tyrosol compounds, 1H NMR was also used to confirm the success of these reactions, since it was 
expected that the halogenated tyrosines would have similar aromatic splitting as those of the 
halogenated tyrosol. As expected the 1H NMR analysis of these compounds all displayed three aromatic 
protons, one of which was a singlet (proton E in Figure 2.12), and two of which were doublets (protons F 
and G in Figure 2.12) suggesting that the desired analogues were successfully synthesized.  
 
Figure 2.12. 
1
H NMR spectra for 3-halogenated tyrosine analogues. a. 
1
H NMR Spectrum for 3-chlorotyrosine. b. 
1
H NMR spectrum for 3--bromotyrsine. c. 
1
H NMR spectrum for 3-iodotyrosine. In each spectrum the peaks labeled 
with letters correspond to the respectively labeled peaks on the compound. The solvent in each case is D2O, 
resulting in the large solvent peak a 4.69 ppm as well as the loss of the amine, carboxyl, and phenol protons in 
each compound. 
 Once the halogenated tyrosines were synthesized, the corresponding HPAA analogues could be 
synthesized. The optimized NaOCl procedure, with DCM as the extraction solvent, gave yields of 83, 82, 
and 62 % for 3-chloroHPAA (25), 3-bromoHPAA (26), 3-iodoHPAA (27) respectively, that were of high 
purity. 1H NMR analysis of each of the compounds suggests that the reactions were successful due to 
the appearance of the characteristic aldehyde peak at 9.74 ppm for 26, and 27, and at 9.75 ppm for 25 
(Peak A in Figure 2.13). In addition to this, there is a loss of the α proton peak in each of the tyrosine 
starting materials (Peak B in Figure 2.13), as well as a change in the splitting for the methylene peak in 
the tyrosines, which changed from a multiplet to a doublet, suggesting that it is now only being split by 
the aldehyde proton (Peak B Figure 2.13). Analysis by GC/MS also confirmed that the expected products 
were successfully prepared displaying M+ of 136 Da for HPAA, which was consistent with the expected 
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mass of 136.15 (Figure 2.14.a). The chlorinated compound displayed an M+ of 170 Da, and an (M+2)+ 
peak characteristic of chlorinated compounds 172 Da, both of which agreed with the expected masses 
of 170.01 and 172.01 Da (Figure 2.14.b). The brominated compound also displayed its characteristic 
mass peaks giving an M+ of 214 Da and an (M+2)+ of 216 Da, which were in agreement with the expected 
masses of 213.96 and 215.96 Da (Figure 2.14.c). Finally, the iodinated analogue displayed an M+ of 262 
Da, which also agreed with the expected mass of 262.04 Da (Figure 2.14.d).  
 
Figure 2.13. 
1
H NMR spectra for 3-halogenated-4-hydroxyphenylacetaldehyde analogues generated via the 
oxidative decarboxylation of halogenated tyrosine analogues. a. 
1
H NMR spectrum for 4-
hydroxyphenylacetaldehyde. b. 
1
H NMR spectrum for 3-chloro-4-hydroxyphenylacetaldehyde. c. 
1
H NMR spectrum 
for 3-bromo-4-hydroxyphenylacetaldehyde. d.
1
H NMR spectrum for 3-iodo-4-hydroxyphenylacetaldehyde. In each 
case, the NMR solvent is CDCl3, which is responsible for the solvent peaks at 7.29 ppm, while the peak at 1.56 ppm 
is water, and peaks at 5.3 ppm are most likely residual CH2Cl2, and the peak at 2.17 ppm is consistent with acetone 
contamination. 
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Figure 2.14. GC/MS spectra for 3-halogenated-4-hydroxyphenylacetaldehyde analogues. a. GC/MS spectrum for 
HPAA. The M
+
 for this compound was 136 Da, which was in agreement with the calculated value of 136.15 Da. b. 
GC/MS spectra for 3-chloro-4-hydroxyphenylacetaldehyde. GC/MS analysis of this compound revealed that the 
resulting M
+
 was 170 with an (M+2)
+
 of 172 Da, both of which are in agreement with the expected values of 170.01 
and 172.02 Da. c. GC/MS spectrum for 3-bromo-4-hydroxyphenylacetaldehyde. This analysis revealed that The M
+
 
for this compound was 214 Da, and the (M+2)
+
 was 216 Da, both of which are consistent with the expected values 
of 213.96 and 215.96 Da. d. GC/MS spectrum for 3-iodo-4-hydroxyphenylacetaldehyde. This analysis resulted in a 
M
+
 of 262 Da which agrees with the expected value of 262.04 Da. 
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2.6 Synthesis of Norcoclaurine Analogues 
   
 Because of the relative instability of HPAA and its analogues, there was concern that they would 
not be suitable substrates for PDB experiments. These types of experiments require the analogues to be 
shaken in liquid media for times greater than one week. Ideally, the substrate should be stable for over a 
week. So in addition to the HPAA analogues, an efficient synthesis of 3-halogenated norcoclaurine 
analogues (44-46) was also developed. The results of an undergraduate teaching lab at DePaul 
University served as the starting point for this synthesis. The lab exercise involved the use of 
norcoclaurine synthase to stereoselectively prepare norcoclaurine analogs from halogenated dopamine 
compounds and HPAA. After analyzing these results, it was discovered that the negative controls which 
contained dopamine, HPAA, and the same phosphate buffer, but no enzyme still produced 
norcoclaurine after incubation in phosphate buffer. These results were also in agreement with the 
reports by Pesnot et al., which also suggested that phosphate was able to catalyze this transformation 
yielding racemic tetrahydroisoquinoline products.25 Based on these results, a biomimetic one-pot 
synthesis of racemic norcoclaurine analogues was developed, that utilized the NaOCl transformation of 
tyrosine to HPAA in phosphate buffer (Scheme 2.7). These reactions were performed by reacting 
tyrosine and the halogenated analogues in the same manner as when producing the HPAA analogues. 
After the tyrosine was consumed, excess NaOCl was quenched through the addition of 0.5 equivalents 
of ascorbic acid, in order to promote a reducing environment. This was followed by the addition of an 
excess of dopamine and the solution was left to stir at 37 oC until the aldehyde was completely 
consumed, leading to the formation of the respective norcoclaurine analogue.  
 
Scheme 2.7. Synthetic route to norcoclaurine analogues, via the newly developed one-pot synthesis from 
tyrosine. Also included is the numbering scheme used to name the analogues. Conditions: i. 1 equivalent of NaOCl, 
phosphate buffer pH 7. ii 1.2 equivalents of dopamine, phosphate buffer pH 7. 
 The synthesis itself was straightforward; however it was necessary to develop a method of 
purification.  It was hoped that the purification method of norcoclaurine reported by Bonamore et al. 
utilizing solid phase activated charcoal extraction to isolate the compound would be applicable to the 
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halogenated analogues as well.50 Although this technique worked to remove the norcoclaurine analogue 
products from the solution, desorbing the analogues from the carbon proved to be difficult. The 
reported method of desorption with 0.005 N ethanolic sodium hydroxide to extract the compound from 
the carbon was unsuccessful in our hands. As a result, several other conditions were considered, 
including methanolic sodium hydroxide, sodium hydroxide in acetonitrile, ethanolic HCl, methanolic HCl, 
and HCl in acetonitrile, all of which failed to release the compound as well. Due to the complications of 
removing the compounds from the activated carbon this approach to purification was abandoned. 
Simple ethyl acetate extraction resulted in the isolation of the desired compounds. Using this one pot 
synthesis allowed for quantitative conversion of the aldehyde to the respective norcoclaurine analogue 
as observed by HPLC measurements, with isolated yields of 28, 45, 48, and 55 %, for norcoclaurine (4), 
3-chloronorcoclaurine (44), 3-bromonorcoclaurine (45), and 3-iodonorcoclaurine (46) respectively. 
Characterization of the products by 1H NMR spectroscopy suggests that these reactions were successful. 
Due to the loss of the aldehyde peaks at around 9.74 ppm, and the appearance of two new singlet 
aromatic peaks, as expected from the structure of the product (labeled as G and H in Figure 2.15.a and H 
and I in Figure 2.15.b-c). The loss of the aldehyde peak, and the appearance of the two singlets is 
consistent with a reaction between dopamine and the aldehyde since dopamine contains two singlet 
aromatic protons. In addition to this, there is an appearance of several new alkyl protons in the range of 
2.5 - 3.3 ppm, consistent with the expected protons in the unconjugated ring of the norcoclaurine 
products (protons C-F in Figure 2.15.a and protons D-G in Figure 2.15.b-d). Although these peaks are not 
well resolved in the spectra, they integrate to values consistent with the expected products, and they 
appear to be similar to previously reported spectra for norcoclaurine like compounds as reported by 
Ruff at al. suggesting that the desired compounds were successfully synthesized.54 
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Figure 2.15 
1
H NMR spectra for 3-halogenated norcoclaurine analogues. a. 
1
H NMR Spectrum for norcoclaurine. 
b. 
1
H NMR spectrum for 3-chloronorcoclaurine.c. 
1
H NMR spectrum for 3-bromonorcoclaurine. d. 
1
H NMR 
spectrum for 3-iodonorcoclaurine. The solvent in Figure 2.15. a, b, and d is methanol-D4, and is responsible for the 
solvent peaks at 4.8 and 3.6 ppm. The solvent for Figure 2.15.c is DMSO-D6 and is responsible for the solvent peak 
at 2.56 ppm, whereas the peak at 3.33 ppm is most likely the due to water. 
 The success of the newly developed one-pot synthesis of norcoclaurine and the related 
analogues was further verified by an enzymatic synthesis of the norcoclaurine and the related analogues 
using the Pictet-Spengler catalyzing enzyme norcoclaurine synthase. This enzyme is known to catalyze 
the condensation between HPAA and dopamine to selectively yield (S)-norcoclaurine, and it has also 
been shown to incorporate a wide variety of phenylacetaldehydes into the corresponding norcoclaurine 
analogues.23, 49, 54 We hoped to verify the production of our norcoclaurine analogues by comparing the 
HPLC retention times between the chemically synthesized norcoclaurine product and the enzymatically 
synthesized products. We hoped that this analysis would reveal that the chemically synthesized 
compounds had the same retention time as the enzymatically synthesized compounds. The results of 
this analysis can be seen in Figure 2.16, which shows eight different chromatograms. Figure 2.16.a and b 
show the results for chemically synthesized and enzymatically synthesized norcoclaurine respectively. 
The identical retention times for both compounds is 2.47 minutes for HPLC condition C (HPLC conditions 
can be found in Appendix A), suggesting that they are the same compound. Figure 2.16 c and d shows 
similar data for 3-chloronorcoclaurine, showing that the retention time for the chemically synthesized 
compound is the same as the retention time for the enzymatic product, with both compounds eluting at 
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1.98 minutes using HPLC condition B. Similarly the retention times for chemically synthesized 3-
bromonorcoclaurine and enzyme synthesized 3-bromonorcoclaurine were the same (Figure 2.16 d and 
e), with the compound eluting at 2.05 minutes (HPLC condition B). This same analysis was also applied to 
3-iodonorcoclaurine resulting in equal retention times under HPLC condition B (Figure 2.16 g and h) of 
2.21 minutes for both compounds. Based on these results it seems that the reported one-pot synthesis 
of norcoclaurine and its analogues was successful.  
 
Figure 2.16. HPLC chromatograms for evaluation of the 1-potsynthesis of norcoclaurine and related halogenated 
analogues from tyrosine and related halogenated tyrosine analogues. a. HPLC chromatogram for norcoclaurine 
synthesized from tyrosine. The retention time was found to be 2.47 minutes (HPLC condition C). b. HPLC 
chromatogram for norcoclaurine synthesized using NCS. The retention time was found to be the same as that of 
the product in Figure 2.16.a. c. HPLC chromatogram for 3-chloronorcoclaurine synthesized from 3-chlorotyrosine. 
The retention time was found to be 1.98 minutes (HPLC condition B). d. HPLC chromatogram for 3-
chloronorcoclaurine synthesized using NCS. The retention time was found to be the same as that of the product in 
Figure 2.16.c. e. HPLC chromatogram for 3-bromonorcoclaurine synthesized from 3-bromotyrosine. The retention 
time was found to be 2.05 minutes (HPLC condition B). f. HPLC chromatogram for 3-bromonorcoclaurine 
synthesized using NCS. The retention time was found to be the same as that of the product in Figure 2.16.e. g. 
HPLC chromatogram for 3-iodonorcoclaurine synthesized from 3-iodotyrosine. The retention time was found to be 
2.21 minutes (HPLC condition B). h. HPLC chromatogram for 3-iodonorcoclaurine synthesized using NCS. The 
retention time was found to be the same as that of the product in Figure 2.16.g. All of these chromatograms were 
generated by plotting the intensity of the maximum absorbance at each time 
2.6 Summary 
 Three different synthetic pathways were attempted and evaluated for their ability to yield the 
desired 3-halogenated-4-hydroxyphenylacetaldehyde analogues. These reactions included reduction of 
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the respective 3-halogenated-4-hydroxyphenylacetic acid compounds to the respective alcohols 
followed by the Parikh-Doering oxidation of those alcohols. A Wittig olefination of 3-halogenated-4-
hydroxybenzaldehyde to yield trapped enol intermediates that can yield the desired 3-halogenatedHPAA 
analogues following acid catalyzed tautomerization was also attempted. A green biomimetic NaOCl 
mediated oxidative decarboxylation of 3-halogenatedtyrosine compounds was also successfully used to 
generate the target molecules. Although the synthesis required several optimization steps, it was 
successfully used to give the desired HPAA analogues cleanly with good yields. This approach yielded the 
desired HPAA analogues in only two steps with cumulative yields of 55, 57 and 19 % for 3-chloroHPAA, 
3-bromoHPAA, and 3-iodoHPAA, respectively. In addition to this, a one-pot biomimetic synthesis of 
racemic 3-halogenatednorcoclaurine analogues from 3-halogenatedtyrosine compounds was also 
developed. This used a phosphate mediated Pictet-Spengler condensation between dopamine and 3-
halogenatedHPAA synthesized from 3-halogenatedtyrosine. This yielded the desired norcoclaurine 
analogues in two steps as well, with cumulative yields of 30, 34, and 17 % for 3-chloronorcoclaurine, 3-
bromonorcoclaurine, and 3-iodonorcoclaurine respectively.  
  
36 
 
Chapter 3 Norcoclaurine Synthase 
3.1 Introduction 
 The first committed step to benzylisoquinoline biosynthesis is the Pictet-Spengler condensation 
of HPAA and dopamine to form the tetrahydroisoquinoline alkaloid norcoclaurine. This reaction is 
catalyzed by the Pictet-Spenglerase enzyme norcoclaurine synthase (NCS).21, 23, 54 As a result of the 
interesting reaction performed by this enzyme and its importance in the biosynthetic pathway of these 
natural products, a considerable amount of work has been performed on this enzyme since its discovery 
in 1981 by Rueffer et al.55 The enzyme was originally named (S)- norlaudanosoline synthase because its 
activity was originally characterized through the observation of the condensation between 3,4-
dihydroxyphenylacetaldehyde and dopamine to form the alkaloid, (S)-norlaudanosoline.55 It was 
eventually renamed after it was discovered that the natural condensation performed in the biosynthetic 
pathway produces norcoclaurine from dopamine and HPAA, rather than norlaudanosoline.56 Recently, 
the mechanism of this enzyme has been proposed by Luk et al.23 and supported by crystal structure 
determination.53 Figure 3.1 displays a summary of the mechanism based on these two works. It is 
believed that the important catalytic residues are; lysine 122 (K122), tyrosine 108 (Y108), and glutamate 
110 (E110), and that the reaction proceeds by the activation of the aldehyde substrate by the K122 
residue of the enzyme. The activation of the aldehyde allows for the nucleophilic attack by the amine 
likely forming a Schiff base intermediate. Deprotonation of the hydroxyl group meta to the 
phenethylamine side chain of dopamine allows for electron density in the ring to undergo nucleophilic 
attack at the imine carbon, closing the ring. The final step of this mechanism includes the 
rearomatization of the dopamine ring system, which is facilitated by a proton abstraction by the E110 
residue of the enzyme.23, 57 The importance of these amino acid residues has been demonstrated 
through site directed mutations of the enzyme. These experiments have shown that the K122 residue is 
the most vital for the catalytic activity, with a K122A mutant showing complete loss of catalytic 
activity.53 Additionally, Y108F and E110A mutants have also been tested for their catalytic activity. Both 
mutants exhibit decreased catalytic activity compared to the wild type enzyme, suggesting that they 
contribute, but are not necessary for, the catalytic activity of this enzyme.53 The crystal structure also 
elucidates how the enzyme controls the stereochemistry of the product. This can be seen in Figure 3.2, 
which shows the two substrates aligned in the active site of the enzyme side by side, thus controlling the 
side of attack by dopamine on the aldehyde substrate. The interactions between the catalytic residues, 
K122 and E110, can also be seen in Figure 3.2, showing a rationale for the proposed mechanism. 
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Figure 3.1. Proposed mechanism of the condensation of HPAA and dopamine by NCS based on the results from 
references 23 and 48. The first step most likely involves the activation of the aldehyde by the K122 residue, 
followed by a nucleophilic attack by dopamine at the aldehyde. This is then followed by the formation of a Schiff 
base intermediate after the loss of water. After this point the phenol meta to the phenethylamine functional group 
is deprotonated allowing for nucleophilic attack by the aromatic ring to occur at the imine, forming the ring. After 
this occurs, E110 of  the enzyme can act as a base to remove the proton and reestablish aromaticity, forming (S)-
norcoclaurine.
23, 53
 
  
Figure 3.2. Crystal structural explanation of the observed stereoselectivity and mechanism of NCS. The left image 
is a close up of the active site of  norcoclaurine synthase detailing the interactions between the catalytic residues, 
K-122, E110, and Y108. It also details the arrangement of dopamine and the aldehyde giving a rationale for the 
enzyme's control over stereochemistry. The right image is a close up of the surface of NCS detailing the active site 
pocket of NCS, and the arrangement of the aldehyde and dopamine substrates. In each case the aldehyde is the 
non-reactive substrate mimic 4-hydroxybenzaldehyde. Color scheme of stick images, blue=N, red = O, green = C. 
Hydrogen is not shown for clarity. The crystal structures were determined in reference 48, and both images were 
generated using PyMOL (PDB ID: 2VQ5).
53, 58
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 Recently, an alternative mechanism for the catalytic activity of this enzyme has been proposed 
by Pesnot et al. based on their work with NCS isolated from Coptis japonica (Figure 3.3).49 This study 
utilized a fluorescamine based assay to study the ability of the enzyme to catalyze the Pictet-Spengler 
reaction between several different aldehyde and amine substrates. Their work revealed that the enzyme 
can incorporate aldehydes with much larger ring systems. Based on this observation, it seemed unlikely 
that the stacked confirmation observed in the crystal structure of NCS is actually occurring since it would 
result in steric clashes. Based on this hypothesis, the researchers performed a series of computational 
substrate docking studies on the enzyme to discover if there is a lower energy docking arrangement that 
the substrates can undergo. The results of this study revealed that dopamine most likely docks first and 
interacts with its meta-hydroxyl, with the amine group pointing towards the opening of the catalytic 
cavity. This is followed by the docking of HPAA, with the aldehyde pointing towards the amine and the 
aldehyde's aromatic ring pointing outwards toward the solvent, thus preventing steric clashes between 
larger side chains and the enzyme. This is then followed by the deprotonation of the amine by aspartatic 
acid 141 (D141), making the amine more nucleophilic and poised for attack on the carbonyl. An imine 
intermediate would then be formed after the loss of water, which is aided by a water channel located 
near the active site of the enzyme. Evidence of this water channel can be seen in Figure 3.4 a and b, 
which shows what appears to be a channel through the center of the protein adjacent to the active site 
that is filled with water molecules.  K122 could then deprotonate the meta hydroxyl in the dopamine 
substrate, catalyzing the ring closure, followed by re-aromatization by E110.  
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Figure 3.3. Proposed mechanism of NCS activity, based on computational studies performed by Pesnot et al.
49
 
This mechanism differs from the mechanism proposed by Ilari et al.
59
 based on a different arrangement of 
substrates. This mechanism involves the docking of dopamine first with dopamine arranged so that the catechol 
points towards the inside of the catalytic cavity while the amine points away from this cavity. This is followed by 
the docking of HPAA in such a manner that the aldehyde points towards the inside of the active site while the 
aromatic region is in the opening partially exposed to solvent (top left). The catalysis first involves the activation of 
dopamine through the deprotonation of the amine by D141, followed by nucleophilic attack of the carbonyl by this 
amine to form the aminol intermediate (top middle). This intermediate then loses water, presumably aided by the 
existence of a water channel (see Figure 3.4), yielding the imine intermediate (top right). From here the key 
catalytic residue, K122 can deprotonate the meta hydroxyl of dopamine while D141 stabilizes this formation 
allowing for the cyclization of the compound (bottom right). The rearomatization of this intermediate is then 
catalyzed by E110 giving the final (S)-norcoclaurine product (bottom left).
49
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Figure 3.4. Structural evidence of the water channel proposed by Pesnot at al.
49
a. Depicts what appears to be a 
channel through the center of the protein. b. Shows the same channel from a different angle to emphasize that the 
channel looks to be accessible from the active site cavity of the enzyme. c. Shows the crystal structure of the NCS 
water channel with the water molecules (blue spheres) present in the crystal structure included. Based on this 
analysis it appears that this opening is filled with water, suggesting that it may function as a water channel. d. 
Water channel with water molecules filled in taken from the same angle as Figure 3.4.b to show that the area 
between that active site cavity and the water channel also contains a water molecule. These images were 
generated in Pymol (PDB ID: 2VQ5).
53, 58
 
3.2 NCS Assay Development and Results 
 Because norcoclaurine synthase represents the first committed step in benzylisoquinoline 
synthesis, it was vitally important that our HPAA and dopamine analogues could be utilized by the 
enzyme to make the respective halogenated norcoclaurine analogues. Previous studies of this enzyme 
found that the enzyme is rather promiscuous and is willing to incorporate several different 
acetaldehydes into  different tetrahydroisoquinoline like products.54 These include various substituted 
phenyl acetaldehydes, including 3,4-dimethoxyphenylacetaldehyde. These results were encouraging and 
an enzymatic assay was developed in order to test the viability of our analogues. The previously 
reported kinetic assay for NCS utilized phosphate buffer, which was troubling because of the high rate of 
background reaction associated with this buffer.23, 25 Because of this, we initially decided to base our 
assay off of the work by Ruff et al. We were encouraged by their HPLC based approach, using methanol 
to quench the reaction at different time points, in TRIS buffer.54  
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 Based on the previously reported Km values for this enzyme of (0.350 ± 0.048) mM for dopamine 
at 37 oC and pH 7.5, and (0.288 ± 0.038) mM for HPAA  at 37 oC and pH 7.5, in conjunction with the fact 
that 2 mM was saturating conditions for both substrates, it was decided to perform our assay using 
sequential 1:1 dilutions of substrate ranging from 0.015 to 2 mM.23 We obtained the same recombinant 
sequence of NCS purified from Thalictrum flavum as the one reported and used by Luk et al., cloned into 
a pET-28a (+) vector as a generous gift from Sarah O'Connor. This vector incorporates an N-terminal His-
tag into the protein, to facilitate purification of the protein using nickel resin affinity chromatography as 
well as a thrombin cleavage site to allow for the removal of the His-tag. The original procedure that was 
developed followed the report by Ruff et al, using 100 mM TRIS buffer at a pH of 7.0. To do this several 
solutions of HPAA were made using eight sequential dilutions starting at 2.11 mM and decreasing to 
0.016 mM. Then a master mix of an enzyme, buffer, and dopamine solution was made that contained 
enough of each solution component to perform nine reactions, so that the final buffer concentration 
would be 100 mM, the final dopamine concentration would be 2 mM, and  the final amount of enzyme 
would be 8.1 µg per assay. To start the reaction, the appropriate amount of this master mix was added 
to one of the tubes containing a HPAA solution. The kinetics were monitored by HPLC by quenching 
samples of the reaction every 2  minutes and 40 seconds, removing a 60 µL sample of the reaction and 
adding 15 µL of methanol containing 0.2 mM naphthalene acetic acid (NAA), with the hopes of 
denaturing the protein.  It was found however, that this quenching procedure was inadequate so the 
conditions were changed to an 80 µL sample of reaction being quenched by the addition of 120 µL of 
methanol, which we found to fully quench the reaction.  
 Once the quenching procedure was worked out, several kinetic runs were performed, using the 
above conditions. However, with all of these attempts we were never able to reach saturating 
conditions with the enzyme, and it was observed that a significant side product was produced (Figure 
3.5). This side product, however, was not observed with imidazole as the reaction buffer, suggesting 
that the side reaction was dependent on the use of TRIS. A further look into the use of TRIS buffer for 
enzymatic assays using aldehyde substrates showed that these issues have been seen before, and result 
from a condensation between the primary amine in the TRIS and the aldehyde forming an imine, which 
is then trapped by one of the free hydroxyl groups forming an oxazolidine product as seen in Figure 
3.6.60 Based on this report, it seems likely that the observed side product is this oxazolidine compound.  
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Figure 3.5. HPLC chromatogram of an enzyme reaction in 100 mM TRIS at pH 7.0. The intensity of the maximum 
absorbance at each time is plotted, yielding the observed chromatogram. As expected, dopamine, HPAA, 
norcoclaurine, and NAA are present along with the appearance of an undesired side product, which is attributed to 
being an oxazolidine containing compound.  
 
Figure 3.6. Reaction scheme detailing the formation of the observed oxazolidine side product. The first step 
involves  the condensation of the primary amine in TRIS and the aldehyde forming an imine intermediate, followed 
by the attack of one of the hydroxyl groups at the imine carbon forming an oxazolidine ring.  
 Due to the appearance of this side product, and the likelihood that it was consuming the 
aldehyde substrate, a new buffer had to be selected that displayed the useful properties of both low 
background reaction and no side reactions. In addition to this, we also wanted to see if the background 
reaction could be quenched by dilution into methanol. As a result a simple assay that would allow for 
the efficient testing of different buffering systems was needed. This assay was designed around the 
necessity to use HPLC as the means of detection, and was largely modeled after the design of the 
previous enzyme kinetic assay reported by Ruff et al.54 In order to test the relative background reactions 
of each species, as well as the quenchability of the background reaction, different tubes containing 2 
mM solutions of both dopamine and HPAA, were allowed to react in a solution containing between 20-
50 mM buffer. This reaction was then injected into the HPLC instrument and the absorbance peak of the 
norcoclaurine product was  monitored at 225 nm, integrated, and plotted against time. Because no 
calibration curve data exists between the integrated area of norcoclaurine and the concentration of 
norcoclaurine, these data were not converted into concentration units and instead the slopes of these 
lines were then taken as the background rate of the Pictet-Spengler condensation. Table 3.1 shows a 
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synopsis of all the tested buffers including the pH tested, the concentration of buffer, the rate of the 
reaction, and the relative rate of reaction as compared to phosphate buffer.  
 In addition to monitoring the background reaction rates, the ability to quench the reaction with 
methanol was also tested by setting up an identical reaction mixture, followed by quenching an 80 µL 
sample with 120 µL of methanol. This reaction mixture was then injected into the HPLC instrument and 
plotted in the same manner as  the background reaction rates by monitoring the production of 
norcoclaurine at 225 nm and plotting the integrated peak area against time. As with the background 
reaction rates, the slope of this line was taken to be the quenched background rate, however in most 
cases the rates were nothing more than random scattering, suggesting that the reaction was completely 
quenched, meaning that this rate is most likely insignificant after quench. Figure 3.7 shows a typical set 
of data for a 25 mM bicine buffer at pH 7.5, showing both the buffer catalyzed background reaction and 
the rate of the reaction after methanol quench. Based on this, there is an obvious difference between 
the background reaction before and after dilution into methanol, suggesting that background reaction is 
effectively stopped by quenching.  
 
 
 
 
Table 3.1: Observed background reaction rates for various buffering systems. 
Buffer pH Rate (µV*s/s) Rate After Quench 
(µV*s /s) 
Percent of 
Phosphate (%) 
(quenched) 
25 mM Phosphate 6.5 1106 -- 100 
25 mM Bicine 7.5 171 1.6 15 (0.15) 
50 mM TRIS 7.5 78.6 -3.2 7.11 (-0.29) 
25 mM HEPES 7 18 0.9 1.64 (0.08) 
25 mM Imidazole 6.5 7.9 -1.2 0.72 (-0.10) 
20 mM Glycine 
Amide 
7.5 8.2 0.6 0.74 (0.06) 
20 mM Maleic 
Acid 
6.7 52 2.0 4.70 (0.18) 
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Figure 3.7. Sample background reaction plots for optimizing buffer conditions for NCS enzyme assays. Each 
reaction was performed using 2 mM of both dopamine and HPAA. The data depicted here is for a 25 mM bicine 
buffer at pH 7.5. In both cases the progress was monitored using HPLC using UV absorbance detection extracted at 
225 nm. The integrated area of the norcoclaurine peak at this wavelength is plotted against time. In each case the 
slope of the line is taken to be the rate of transformation. The slope of the line for the unquenched bicine reaction 
is 171 µV*s /s, while the slope of the line for the quenched reaction is 1.6 µV*s /s. 
 Based on the results shown in Table 3.1 it was decided that the best buffering system is an 
imidazole buffer at pH 6.5, which showed a very small amount of background reaction, and was fully 
quenchable using our quench method. The procedure was repeated using a 25 mM imidazole buffering 
system (pH 6.5) by running a series of reactions each containing 4 mM of the dopamine substrate and 
varying concentrations of HPAA from 2.1 to 0.13 mM. The reactions were followed by mixing the 
appropriate amounts of substrates, buffer, and enzyme into a vial and making repeated injections of this 
solution into the HPLC. The reaction progress was monitored by following the absorbance of the 
norcoclaurine peak at 225 nm using HPLC. The integrated area of the norcoclaurine peak at 225 nm was 
then plotted as a function of time to determine the rates of reaction in units of µV*s/s, in lieu of a rate 
in terms of concentration units as no conversion currently exists. Because concentration and absorbance 
are linearly related to one another, the rates acquired in these units should be easily converted to more 
traditional rates in terms of concentration per time once a calibration curve that relates the two has 
been established. Analysis of the results were performed by plotting these rates as a function of HPAA 
concentration and using non-linear regression software to fit the data to the Michaelis-Menten equation 
(eq. 3.1). 
 
   
       
      
 
(3.1) 
in Eq. 3.1 v is the rate of the reaction, Vmax is the maximum rate of the reaction after saturation of the 
enzyme, [S] is the concentration of substrate, and KM is the Michaelis constant, and is equal to the 
concentration of substrate at half saturation. Fitting these results to eq. 3.1 resulted in the curve seen in 
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Figure 3.8 yielding a KM value of (1.1 ± 0.4) mM for the aldehyde substrate. This however, is significantly 
higher than the previously reported value of( 0.288 ± 0.38) mM.23  
 
Figure 3.8. Experimental kinetics data for the NCS enzymatic assay in 25 mM imidazole buffer at pH 6.5 using a 
continuous injection method. The graph on the left shows the plots used to determine the rates of enzyme 
catalysis. In each case the production of norcoclaurine was monitored using HPLC by integrating its peak at 225 
nm, and plotting the change as a function of time. The slopes were found to be 3280, 2650, 1860, 750, and 310 
µV*s/s for 2.1, 1.05, 0.525, 0.263, and 0.131 mM HPAA respectively. These rates were used to generate the 
Michaelis-Menten Curve on the right for NCS for the substrate HPAA in 25 mM imidazole buffer at pH 6.5. The data 
were fit to eq. 3.1 resulting in a Km value of (1.1 ±0.4) mM.  
 Although the difference in the observed KM and the reported value could be attributed to the 
differences in temperature and pH between our study and the reported study, we still wanted to see if 
we could observe a curve that reached full saturation. So this test was then repeated using methanol 
quenches to monitor the rate of the reaction, and a higher maximum concentration of HPAA. During this 
evaluation, the maximum concentration of HPAA was increased to 3.2 mM and eight samples were 
prepared with concentrations from 0.03 - 3.2 mM HPAA. The progress of this reaction was then 
monitored by making quenches every 30 seconds by diluting an 80 µL sample of the reaction mixture 
into 120 µL of methanol, and following the area of the norcoclaurine peak at 225 nm. The data analysis 
was performed using the procedure stated above, resulting in the plot shown in Figure 3.9. The results 
of this plot yielded a curve that does not appear to reach the saturation point of the enzyme and a KM of 
(2.6 ± 0.2) mM, which is an order of magnitude larger than the literature value for this substrate and 
enzyme.23  
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Figure 3.9. Experimental kinetics data for the NCS enzymatic assay in 25 mM imidazole buffer at pH 6.5 using the 
methanol quench procedure. The graph on the left shows the plots used to determine the rates of enzyme 
catalysis. The production of norcoclaurine was monitored using HPLC by following and integrating its peak at 225 
nm, and change was plotted as a function of time. The slopes were found to be 5330, 3580, 2240, 1370, 680, 340, 
180, and 60 µV*s /s for 3.2, 1.6, 0.80, 0.40, 0.20, 0.10, 0.05. and 0.025 mM HPAA HPAA, respectively. These rates 
were used to generate the Michaelis-Menten curve on the right for NCS for the substrate HPAA in 25 mM 
imidazole buffer at pH 6.5. The data were fit to eq. 3.1 resulting in a Km value of (2.6 ± 0.2) mM.  
 Discouraged by this result, we decided to test to see if another buffering system would yield 
different results. Based on the results shown in Table 3.1, HEPES was chosen based on its low rate of 
background reaction and quenchability. As with the imidazole studies, these reactions were performed 
using differing concentrations of HPAA in the presence of a constant concentration of dopamine in a 25 
mM HEPES buffer (pH = 7.0). The data analysis was also performed as described above, resulting in the 
two curves shown in Figure 3.10. In each case, the maximum concentration of HPAA tested was 2.7 mM, 
and sequential 1:1 dilutions were made ranging from 2.7 - 0.021 mM HPAA, while dopamine was held 
constant at 2.25 mM. Fitting of the results of Figure 3.10.a and Figure 3.10.b resulted n KM values of 
(0.350 ± 0.095) mM and (0.498 ± 0.082) mM respectively. This yielded an average KM value of (0.42 ± 
0.06) mM, which is far closer to the previously reported values of ( 0.288 ± 0.38) mM at for this 
enzyme.23 
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Figure 3.10.Michaelis-Menten curves for HPAA in 25 mM HEPES buffer pH 7.0. Both experiments utilized a range 
of concentrations from 0.021 to 2.7 mM HPAA, while the reaction was monitored by HPLC with UV detection at 
225 nm by integrating the area of the resultant norcoclaurine peaks, and plotting the change in this area against 
time to obtain a rate. The results were fit to Eq. 3.1 the curve in Figure 3.10.a  results in a KM of (0.350 ± 0.095) mM 
whereas the curve in Figure 3.10.b results in a KM of (0.498 ± 0.082) mM, yielding an average KM of 0.42 ± 0.06 mM.  
 Encouraged by these results, the experiments were repeated with the hopes of determining a 
Km for dopamine. These experiments were designed to be analogous to the previous assays, but altering 
the concentration of dopamine while maintaining a constant HPAA concentration. Using the same 25 
mM HEPES buffer at pH 7.0, these reactions were repeated using concentrations of dopamine ranging 
from 0.18 to 2.9 mM, in the presence of 2.25 mM HPAA. Once again the kinetics were monitored by 
quenching the reactions every 2  minutes and 40 seconds, and monitoring the change in the integrated 
area of the norcoclaurine absorbance peak at 225 nm, as a function of reaction time. These rates were 
then plotted against the respective concentration of dopamine, resulting in the curve seen in Figure 
3.11.a. This curve, however, did not appear to reach saturation, resulting in a KM of (3.9 ± 0.2) mM. 
Based on the observation that the kinetics never seemed to have reached saturation, a second test was 
performed using a wider range of dopamine concentrations ranging from 0.033 to 4.2 mM, yielding the 
curve shown in Figure 3.11.b. Once again the results were discouraging, resulting in another curve that 
failed to reach saturation and a very large KM of (4 ± 1) mM and an average KM of (4.0 ± 0.4) mM. Once 
again, this is an order of magnitude higher than the reported KM of (0.350 ± 0.048) mM.
23 
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Figure 3.11. Michaelis-Menten curves for dopamine in 25 mM HEPES buffer pH 7.0. In each experiment, the 
reactions were monitored by HPLC after methanol quench. The results of both curves were then fit to Eq. 3.1 with 
the data in Figure 3.11.a yielding a KM of (3.9 ± 0.2) mM and the data in Figure 3.11.b yielding a KM of (4 ± 1) mM.  
 Once again these results can be explained by  the differences in both temperature and pH 
between the reported assay and the observed values. However, because saturation was never achieved, 
we decided to test another buffer, 25 mM maleic acid (pH 6.7). As with all of the other assays, these 
reactions were monitored using the methanol quench procedure along with HPLC separation followed 
by UV detection of the norcoclaurine peak at 225 nm. The rates were determined by plotting the change 
in the area of the norcoclaurine peak against time in seconds yielding rates with units of µV*s/s. With 
this buffering system, experiments to determine a KM for both HPAA and dopamine were performed. 
The HPAA varied experiment tested concentrations of HPAA from 0.032 to 4.0 mM, with methanol 
quenches being performed every 2 minutes and 40 seconds. Figure 3.12.a displays the curve resulting 
from this experiment, which after plotting the observed rates against concentration of HPAA and fitting 
to Eq. 3.1 yielded a KM of (1.6 ± 0.3) mM. The dopamine varied experiment was performed and analyzed 
in an identical manner, with the exception that the concentrations tested ranged from 0.026 to 3.34 
mM. Figure 3.12b shows the Michaelis-Menten plot for this reaction, yielding a KM of (0.76 ± 0.08) mM.  
49 
 
 
Figure 3.12. Michaelis-Menten plots for enzyme reactions in Maleic acid buffer. a. Michaelis-Menten plot for 
HPAA in 25 mM maleic acid buffer pH 6.7. Fitting of this curve to Eq. 3.1 resulted in a KM of (1.6 ± 0.3) mM. Figure 
3.12.b. Michaelis-Menten plot for dopamine in 25 mM maleic acid buffer pH 6.7. Fitting of this plot resulted in a KM 
of (0.76 ± 0.08) mM. the progress of reaction was monitored by HPLC by monitoring the integrated area of the 
norcoclaurine peak at 225 nm. The resulting areas were plotted as a function of time yielding the rates in units of 
µV*s /s. These rates were then plotted against the concentration of substrate and the curves were fit to Eq. 3.1.  
 The results of this study were encouraging because this was the first buffering system that 
appeared to result in saturation of the enzyme for dopamine, and was the first buffering system to yield 
a reasonable KM for the dopamine substrate. However, when these experiments were repeated, this 
trend was not observed, and instead the enzyme reactions were once again found to not reach 
saturation, and resulted in unreasonably large KM values. Figure 3.13 displays the result of one of these 
assays, resulting in a KM of (2.6 ± 0.6) mM. After a further analysis of the data, it appeared that each rate 
was double the rate of the one for the concentration below it, resulting in linear trends rather than the 
expected hyperbolic trend typically associated with enzyme catalysis. Table 3.2 and Figure 3.14 show a 
sample of data that followed this trend, yielding a linear Michaelis-Menten plot and a KM of (33 ± 4) mM. 
Based on this result, it appeared that the reaction was dependent only on the concentration of 
substrate, and it was thought that we were only observing background reaction, and not enzyme 
catalysis.  
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Figure 3.13. Michaelis-Menten curve showing results showcasing that the enzyme reactions fail to reach 
saturation. The KM value for this sample was found to be (2.6 ± 0.6) mM after fitting to Eq. 3.1.  
 
Table 3.2: Concentrations and resulting rates for a dopamine varied experiment. 
[Dopamine] 
(mM) Rate (µV*s /s) 
3.7 2143 
1.9 1152 
0.93 579 
0.46 303 
0.23 148 
0.12 73.9 
0.058 44.3 
0.029 27.2 
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Figure 3.14. Michaelis-Menten curve for the data in Table 3.2. The data in this plot appear to increase almost 
linearly rather than hyperbolically, with each rate appearing to be approximately twice the rate of the rate for the 
concentration below it. The KM resulting from this data was found to be (33 ± 4) mM after fitting to Eq. 3.1. 
 Based on this observation, a new expression of NCS was performed and several enzyme assays 
were performed, all of them unfortunately yielding similar results where saturation was never reached, 
yielding greatly inflated KM values. When looking into the data, more closely it was noticed that the rates 
were not extrapolating to 0 AU absorbance at 0 seconds time, and that this effect was more pronounced 
the longer the samples were waiting before injection into the HPLC (Figure 3.15). It was also noticed that 
even when capped the level of solution in the vials was noticeably lowered after the samples had 
completed running. Based on this evidence it seemed likely that the methanol was evaporating while 
the samples were awaiting injection. Based on this knowledge, we decided to incorporate a new quench 
method into the procedure that prevented the use of volatile organic solvents in the hope that it would 
result in cleaner data. This method involved the use of 1 M HCl to quench the solution by lowering the 
pH to <2 by adding 20 µL of 1M HCl into 80 µL of reaction sample. This pH was chosen based on the 
observation that the background reaction at this pH was negligible even when performed in phosphate 
buffer, and the enzyme was fully quenched at this pH. Using this procedure another assay was 
performed. In this case the rates extrapolated back to zero (Figure 3.16), but the reaction still failed to 
reach saturation and yielded inflated KM values. 
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Figure 3.15. Sample kinetic data for an enzyme assay using the previously stated methanol quench procedure. In 
each case, the rates fail to extrapolate back to zero suggesting that evaporation of the solution is occurring while 
the samples await injection into the HPLC.  
 
Figure 3.16. Sample kinetic data for an enzyme assay using the newly developed HCl quench method. In each 
reaction samples are quenched by the addition of 20 µL of 1 M HCl into 80 µL of reaction sample. This data reveals 
that the rates extrapolate to a value much closer to 0 suggesting that less evaporation is occurring.  
 Even when the highest concentration of HPAA was increased to an order of magnitude higher 
than the previously reported saturation point of the enzyme by Luk et al. (10.73 mM), saturation was 
not achieved, and the resulting KM was (6 ± 1) mM (Figure 3.17). These results were disappointing 
because they suggest that there is something wrong with the enzyme itself. When looking into the 
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differences between the construct tested in our lab and the one used by Luk et al. it was discovered that 
our enzyme contained an N-terminal His tag, while the one used by Luk et al. contained a C-terminal tag. 
A second look at the crystal structure then revealed that the protein crystallizes as a dimer, which was in 
agreement with the results by Luk et al. that the activity of this protein on the dopamine substrate 
displays cooperative binding, with a Hill coefficient of 1.98.23, 61 The cooperative nature of this enzyme 
suggests that it behaves as a dimer in solution as well. This was an important discovery since the crystal 
structure reveals that when dimerized, the N-terminus of the protein is close to the site where the two 
peptides form a dimer, and it is possible that the extension of the N-terminus by adding a His tag can 
prevent the protein from dimerizing and decrease its activity. This seems to be supported by our results 
as we have never observed sigmoidal kinetics consistent with the expected cooperative binding, and a 
Hill coefficient of ~2. Additionally, previously reported observations by Samanani et al. also note that 
altering the N-terminus of NCS may alter its activity. In this report, recombinant NCSΔ10 was cloned into 
a PET29b vector between the BamHI and XhoI restriction sites. Incorporation into these sites resulted in 
a C-terminal His tag, and the addition of an approximately 4 kDa peptide chain on the N-terminus. The 
kinetic studies performed using this protein also resulted in a reduced activity, with KM values 
approximately twice those of the natural enzyme.61 This suggests that the decreased activity could result 
from the extended N-terminus, which may prevent the proteins from forming the dimer, and thus 
preventing its cooperative activity from occurring. Currently we are awaiting the delivery of the exact 
construct used by Luk. et al. in order to determine if the issues we are having with the inconsistency of 
this enzyme's activity is related to the N-terminal His tag, after which these experiments will be 
repeated with the hopes of yielding an enzyme that delivers KM values consistent with those described 
in the literature. Once that has been achieved, we then hope to characterize the kinetics of our 
analogues by determining their KM as well. 
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Figure 3.17. Kinetics data for an HPAA varied experiment where the highest concentration of HPAA is 10.7 mM. 
From these data it appears that the enzyme is not saturated even at concentrations an order of magnitude higher 
than the values reported by Luk et al.
23
 
3.3 Evaluation of Unnatural HPAA analogues as Substrates for NCS 
 Based on the realization that the major issue with these assays can be attributed to issues in the 
structure of the enzyme, it was decided to abandon any attempts to characterize the enzyme in terms of 
its KM and instead an approach similar to the one used by Ruff et al. and Presnot et al. was taken. These 
studies characterized the ability of the enzyme to turn over the substrate using a single point kinetic 
approach, where they ran an enzyme reaction using either the native substrate or analogues  for a set 
amount of time and then quenched the reaction and determined the percent turnover of that substrate. 
Although this information was interesting, the value of a single data point reveals very little about the 
enzyme itself, and instead we decided to run side by side reactions to gather rate data for the analogues 
relative to the natural substrate. In order to ensure that the data was as accurate as possible, all of the 
reactions were performed side by side using solutions containing 1 mM HPAA (or analogue). In order to 
ensure that a uniform amount of enzyme, dopamine, and buffer were present in each reaction, a large 
master mix solution containing all three was made. The reactions were then started by the addition of 
enough of this solution so that the final concentration of dopamine would be 1 mM, final concentration 
of HEPES would be 100mM (pH 7.2), and the final concentration of enzyme would be 11 µg per reaction. 
Each reaction was then quenched at 1 minute time points through the addition of 20 µL of 1 M HCl into 
80 µL of reaction. These quenches were then analyzed by HPLC by monitoring the area of the product at 
225 nm, and plotting these values as a function of time to yield a rate in units of µV*s /s. These rates 
were then reported as a percent of the HPAA rate. These experiments were performed in triplicate, with 
a new HPAA control being run every time, so a direct comparison could be made between runs. The 
compounds tested were: HPAA (3), 3-chloroHPAA (25), 3-bromoHPAA (26), and 3-iodoHPAA (27). Table 
3.3 details the result of this study, in which relative rates of (45 ± 4)%, (63 ± 6)%, and (67 ± 9)% for 
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analogues 25, 26, and 27, respectively. In addition to this, negative controls were performed, using 
added buffer rather than enzyme to confirm that the products formed were resulting from enzyme 
catalysis and not background buffer catalysis. These tests resulted in no detectable norcoclaurine 
products, suggesting that the products seen were formed through enzyme catalysis. Currently, 
experiments to further verify the enzyme's activity and stereoselectivity are being performed using 
chiral HPLC to separate the two enantiomers. Initial results of these experiments suggest that only the S-
enantiomer is present when norcoclaurine is synthesized using enzyme catalysis, further confirming the 
enzyme's activity.  
Table 3.3. Rates of tested HPAA analogues relative to the natural substrate HPAA (3). The reported error is the 
standard deviation through three trials. 
Compound Number Structure Rate relative to HPAA (%) 
3 
 
100 
25 
 
45 ± 4 
26 
 
63 ± 6 
27 
 
67 ± 9 
 
 The results of these experiments were interesting because they suggest that the larger and less 
polar 3-bromo and 3-iodoHPAA analogues are more easily taken up by the enzyme that the smaller 
more polar 3-chloroHPAA analogue, as seen by approximately a 20 % decrease in the relative rate for 
this compound over 26 and 27. One possible explanation for this observation is that the less polar 
analogues have better interactions with  the amino acid side chains that make up the HPAA binding site 
(F99, F80, Y108, L76, and M183).49 This could result in a much more favorable fit in the active site for 
these less polar analogues, which may result in favorable activity over that of the more polar chlorinated 
compound. Even though they display a decreased rate, the results of this study are encouraging, since 
they suggest that the analogues can successfully be transformed by the enzyme into the respective 
norcoclaurine analogues, and thus make it through the first committed step of benzylisoquinoline 
biosynthesis. This suggests that these analogues maybe useful as precursor analogues in PDB type 
experiments of berberine and related alkaloids.  
3.4 Summary 
 Norcoclaurine synthase catalyzes the first committed step to benzylisoquinoline biosynthesis, by 
catalyzing the stereoselective Pictet-Spengler reaction between dopamine and HPAA. Because of the 
enzyme's importance in the biosynthetic pathway of berberine it is vitally important that the 
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synthesized 3-halogenatedHPAA analogues can be transformed into norcoclaurine analogues by the 
enzyme if they are to be useful in PDB experiments of berberine. Several attempts to develop a useful 
kinetic assay for this enzyme were performed using HPLC to monitor the reaction. These assays tested 
different buffers, pH, concentration, and substrate concentrations with the hope of observing Michaelis-
Menten saturation, and characterizing the kinetics by determining KM values for the different substrates. 
Ultimately these attempts proved unsuccessful, and it appears that the reason for this maybe due to the 
N-terminal His tag attached to the construct tested in this assay. Instead the rates of the different 
analogues were measured under identical circumstances. The rates were then reported relative to the 
rate of the native substrate (HPAA), yielding relative rates of (45 ± 4), (63 ± 6), and (67 ± 9) % of the rate 
for HPAA. Monitoring of the background reaction yielded no detectable norcoclaurine product 
suggesting that the observed catalysis was performed by the enzyme. These results suggest that the 
analogues are capable of entering the biosynthetic pathway of berberine. Currently studies are being 
performed to demonstrate that the enzyme is yielding enantiomerically pure norcoclaurine through the 
use of chiral HPLC separation. In addition to this, work is being done to confirm that the N-terminal His 
tag is responsible for the decreased activity that our construct displays, including the use of thrombin to 
cleave the His tag. We also plan to obtain the construct used by Luk et al. and perform related 
experiments using this enzyme as well.    
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Chapter 4 Tyramine Analogues 
4.1 Introduction 
 In addition to the study of the berberine biosynthetic pathway, it was also desired to study the 
biosynthesis of galanthamine through the use of precursor directed biosynthesis. Of the several 
precursor compounds available for study, we decided that tyramine analogues were the most suitable. 
This meant that an efficient method for producing halogenated tyramine analogues was necessary. In 
this case, two methods were examined. The first step of both of these pathways was the halogenation 
of 4-hydroxybenzaldehyde, as explained in section 4.2. The first of these pathways involved converting 
the synthesized 3-halogenated-hydroxybenzaldehyde compounds (29,30) into the corresponding 3-
halogenated-4-hydroxynitrostyrene (47,48), followed by a zinc mediated reduction to the corresponding 
3-halogenatedtyramine analogues (49,50) (Scheme 4.2).62 This method was desirable because it would 
allow for an efficient synthesis of the desired compounds using only three reactions: halogenations 
nitro-aldol condensation followed by reduction. The second strategy was modified from the report by 
Weinstock et al. and also started with 3-halogenated-4-hydroxybenzaldehyde (29,30), with the first step 
being phenol protection to yield the corresponding 3-halogenated-4-methoxybenzaldehyde compounds 
(31,32). These compounds could then be reduced to the corresponding 3-halogenated benzyl alcohol 
(51,52) allowing for the conversion to the corresponding 3-halogenated benzylchloride (53,54), allowing 
for the an SN2 type reaction with the cyanide anion to form the respective benzylcyanide (55,56). Finally, 
the benzylcyanide compounds can be reduced to the 3-halogenated-4-methoxytyramine analogues 
(57,58), and deprotected to give the desired tyramine analogues (Scheme 4.3).63 Although this was 
significantly more steps than the other strategy, each of the reactions to be utilized were reported to 
have high yields, rapid reaction times, and minimal work up necessary, which made this strategy 
attractive.  
4.2 Chlorination and Bromination of 4-hydroxybenzaldehyde 
 As previously stated, 28 was the starting material for both synthetic strategies, and the 
halogenations were performed as described in Chapter 2 using SO2Cl2 and NBS for chlorination and 
bromination, respectively. These reactions went smoothly, producing 3-chloro-4-hydroxybenzaldehyde 
(29), and 3-bromo-4-hydroxybenzaldehyde  (30) with yields of 61 and 86 % respectively (Scheme 4.1). 
This was due to each reaction having a unique mechanism to promote monohalogenation. In the case of 
chlorination, the halogenated product precipitates from solution preventing it from further reaction, 
whereas the reaction with NBS utilizes toluene sulfonic acid as a directing reagent, physically blocking 
the second halogenation site from being able to react (see chapter 2, Figure 2.5) for a more in depth 
discussion).37  
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Scheme 4.1. Halogenation of 4-hydroxybenzaldehyde. Conditions: i. SO2Cl2, acetic acid (RT). ii. N-
bromosuccinimide, acetonitrile, p-toluenesulfonic acid (RT).  
 The confirmation of these products was achieved through 1H NMR spectroscopy and GC/MS 
(Figure 4.1 and Figure 4.2). In particular, changes in the aromatic peaks were used to determine that the 
halogenation was successful. In each case, it was expected that the two aromatic doublets in the 
starting material would shift to form three aromatic peaks each representing one proton. In addition it 
was expected that these peaks would include one singlet and two doublets. As expected the 1H NMR 
spectra show these peaks, although the expected singlet (proton B in Figure 4.1) also shows some long 
distance coupling to the proton on the other side of the aldehyde (proton C in Figure 4.1). This is 
evidenced by peak B having a small degree of doublet character, while peak C appears as a doublet of 
doublets. GC/MS data for these compounds also suggests that the desired compounds were produced 
by these reactions. The mass spectrum for compound 29 yielded an m/z of 156 Da, and the 
characteristic (M+2)+ peak of 158 Da, that is typically associated with the presence of a chlorine. 
Similarly, GC/MS analysis for compound 30 was also in agreement with the expectations for this 
compound, yielding an m/z of 200 Da, with the characteristic (M+2)+ peak at 202 Da, which are in 
agreement with the expected masses of 199.95 and 201.95 Da for the major isotopes of this compound 
(Figure 4.2).   
 
Figure 4.1. 
1
H NMR Spectra for 3-halogenated-4-hydroxy benzaldehyde Compounds. a 
1
H NMR Spectrum for 3-
chloro-4-hydroxybenzaldehyde. b. 
1
H NMR spectrum for 3-bromo-4-hydroxybenzaldehyde. In both cases the 
labeled peaks correspond to the labeled protons in the picture.  
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Figure 4.2. GC/MS Spectra for 3-halogenated-4-hydroxybenzaldehyde compounds. a. GC/MS spectrum for 3-
chloro-4-hydroxybenzaldehyde. Analysis of this compound resulted in a M
+
 of 156 with a percent abundance of 70 
%and a (M+2)
+
 of 158 with a percent abundance of 21 %, both consistent with the expected values of 156.00 and 
157.99 Da. The appearance of a (M+2)
+
 peak that is approximately 30 % of the M
+
 is also consistent with the 
addition of a chlorine atom, due to chlorine having two major isotopes. b GC/MS spectrum for 3-bromo4-
hydroxybenzaldehyde. Analysis of this compound resulted in a M
+
 of 200 with a percent abundance of 55 % and a 
(M+2)
+
 peak of 202 with a percent abundance of 60 %, both of which are consistent with the expected values of 
199.95 and 201.95 Da. The appearance of an (M+2)
+
 peak that is approximately equal in abundance to the M
+
 is 
also consistent with the incorporation of a bromine atom due to bromine having two major isotopes that are 
approximately equal in percent abundance.  
 
4.3 Nitro-aldol Attempt at generating tyramine analogues  
 Once the halogenations were complete, the generation of tyramine analogues using a nitro-
aldol approach was evaluated (Scheme 4.2). These reactions were relatively straightforward yielding the 
3-halogenated-4-hydroxynitrostyrenes by reflux of the benzaldehyde in nitromethane in the presence of 
ammonium acetate, giving excellent yields of 94 % for both 3-chloro-4-hydroxynitrostyene (47) and 3-
bromo-4-hydroxynitrostyrene (48) after extraction into diethyl ether and rotary evaporation. As can be 
seen from the 1H NMR of these compounds, there is a new set of doublets that are coupled to one 
another, and appear to be in a conjugated system. For compound 47, these peaks appear as broad 
doublets at 7.97 – 7.88 and 7.52 ppm, while for compound 48, they appear at 7.92 and 7.53 ppm, for 
protons labeled as A and B (Figure 4.3).  
 
Scheme 4.2. Nitrostyrene route to 3-chloro-4-hydroxytyramine and 3-bromo-4-hydroxytyramine. Conditions: i. 
ammonium acetate, nitromethane (reflux). ii. Zn dust, 1:1 concentrated HCl: methanol (< 4
 o
C).  
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Figure 4.3. 
1
H NMR spectra for 3-halogenated-4-methoxybenzaldehyde compounds. a. 
1
H NMR spectrum for 3-
chloro-4-hydroxyphenylnitrostyrene. b. 
1
H NMR spectrum for 3-bromo-4-hydroxynitrostyrene. The lettered peaks 
correspond to each of the respective lettered protons. The solvent used in these spectra is CDCl3 and is responsible 
for the peak at about 7.29 ppm. The peak at about 1.56 ppm is most likely water.  
 After successfully synthesizing the two nitrostyrene compounds in high yield, a method of 
reducing the nitrostyrene to the phenethylamine had to be established. For this procedure a zinc 
mediated reduction in the presence of HCl was attempted, which utilizes the reaction between zinc an 
HCl to generate hydrogen gas, which can then serve as the reducing agent for the nitrostyrene 
compound to yield the respective phenethylamine.62 Based on previous work performed in our lab, it 
was known that this reaction is strongly dependent on temperature, and the reaction must be kept at 
temperatures < 4 oC. Based on these results, the general procedure for this reaction called for a 1:1 
solution of concentrated HCl in methanol to be cooled in an ice/salt water bath. In addition to the ice 
bath, the zinc and nitrostyrene had to be added in alternating portions over 2 hours in order to prevent 
the reaction temperature from rising too quickly.  This reaction was attempted twice and gave 
inconsistent results. HPLC analysis of the first time it was attempted appeared to yield one major 
product, but when this was repeated several side products were observed as seen in  Figure 4.4. In 
addition to this, all attempts to purify the desired compound failed, yielding total product loss. This 
resulted in an inability to characterize the products of this reaction to ensure that the observed product 
was in fact 3-chlorotyramine. Due to the inconsistencies observed from this reaction, it was decided it 
would be better to pursue another route to the desired compounds rather than attempt to optimize this 
reaction.  
61 
 
 
Figure 4.4. HPLC analysis of the products for the zinc reduction of 3-chlorotyramine. The initial attempt (top) 
produced one major product, while the second attempt (bottom) produced several side products. In both 
chromatograms the intensity of the maximum absorbance at each time is plotted.  
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4.4 Successful Generation of tyramine analogues 
 After this initial attempt to convert the nitrostyrene products into the respective tyramine 
analogues, the method of synthesizing phenethylamines reported by Weinstock et al. was attempted.63 
This scheme of reactions also started with 28, which was then halogenated to either 29 or 30. These 
could then be reduced to the corresponding benzyl alcohols, transformed into benzyl chlorides, 
extended by one carbon to make the benzyl cyanides, and finally reduced to the corresponding 
phenethylamines (Scheme 4.3). The first step required the protection of the phenol, which was achieved 
through an SN2 type reaction between the phenol and iodomethane in the presence of NaOH. These 
reactions were relatively straight forward and gave good yields of 79 and 81 % for compounds 31 and 
32, respectively, after filtration through a silica plug. The evidence that this was achieved can be seen in 
the 1H NMR spectra for these compounds, which display a new singlet peak at  4.02 ppm for compound 
31 and 4.00 ppm for compound 32. This new peak integrates to three protons and is within the range of 
what is expected for a methoxy proton, suggesting that this new functional group was successfully 
added (proton E in Figure 4.5 a and b). In addition to this, GC/MS analysis of the products yielded an m/z 
of 170 Da and a (M+2)+ of 172 Da for compound 20, both of which agreed with the calculated values of 
170.01 and 172.01 Da (Figure 4.6.a). GC/MS analysis of compound 32 also yielded a M+ of 214 Da and a 
(M+2)+ of 216 Da, which agree with the expected values of 213.96 ad 215.96 Da (Figure 4.6.b).  
 
 
Scheme 4.3. Nitrile synthetic route to halogenated tyramine analogues. Conditions: i. methyl iodide, CH2Cl2, 2 M 
NaOH, tetrabutylammoniumhydrogen sulfate (RT). ii. NaBH4, CH2Cl2 (RT). iii. SOCl2, CH2Cl2 (RT). iv. NaCN, DMSO, 
(40 
o
C). v. BH3-THF complex (reflux). vi. 48 % HBr (reflux). Yields reported in parenthesis are impure.  
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Figure 4.5 
1
H NMR spectrum for 3-halogenated-4-methoxybenzaldehyde compounds. a. 
1
H NMR spectrum for 3-
chloro-4-methoxybenzaldehyde. b. 
1
H NMR spectrum for 3-bromo-4-methoxybenzaldehyde. In each spectrum, the 
labeled protons correspond with their respective peaks. In both cases, the solvent is CDCl3 resulting in the solvent 
peak at 7.29 ppm. the solvent peak at 1.56 ppm is most likely due to water.  
 
Figure 4.6.GC/MS spectra for 3-halogenated-4-methoxybenzaldehyde compounds. a. GC/MS spectrum for 3-
chloro-4-methoxybenzaldehyde. The M
+
 for this compound was found to be 170 Da with an (M+2)
+
 of 172 Da, both 
of which are consistent with the expected values of 170.01 and 172.01 Da, for this compound. The mass fragments 
at 169 Da and 171 Da are consistent with the loss of the aldehyde proton for the compound resulting in fragments 
that are 1 mass unit less, but still showing the characteristic chlorine isotopic abundance. b. GC/MS spectrum for 3-
bromo-4-methoxybenzaldehyde. The M
+
 for this compound is 214 Da with an (M+2)
+
 of 216 Da, which are both 
consistent with the expected masses of 213.96 and 215.96 Da. The mass peaks of 213 Da and 215 Da suggest the 
loss of the aldehyde proton as well, resulting in fragments that are 1 unit less, but still showing the characteristic 
bromine isotopic abundance. In both spectra the inset is added to emphasize the molecular ions and the 
characteristic isotopic ratios resulting from the chlorine and bromine atoms.  
 The next reaction in the series was a reduction of the benzaldehyde to a benzyl alcohol using 
NaBH4. Once again this reaction worked very well requiring only 0.7 equivalents of the borohydride and 
1 hour of stirring at room temperature. The only issue with this reaction was that there were some 
residual impurities left over after extraction, which can be seen in the 1H NMR spectra for these 
compounds (Figure 4.7 a and b). Because of this, the calculated yields were artificially high values of 120 
% and 93 % for compounds 51 and 52, respectively. Although these impurities were worrisome, it was 
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discovered that they did not impact the results of the next reaction so they were not dealt with as it was 
hoped they could be removed more easily after the future steps. The 1H NMR spectra for these 
compounds show that the reductions were successful, as they show a disappearance of the aldehyde 
peak around 9 ppm, and in both cases a new triplet is observed. The presence of this triplet is consistent 
with a primary alcohol proton that is being split by the two methylene protons found adjacent to it. In 
addition to this, GC/MS analysis of compound 51 resulted in an m/z of 172 Da and an (M+2)+ of 174 Da, 
which is consistent with the molecular weights of 172.03 and 174.03 Da for this compound (Figure 
4.8.a). Similarly for compound 52 the GC/MS yielded an m/z of 216 Da with an (M+2)+ of 218 Da, which 
are also consistent with the expected molecular weights of 215.98 and 217.98 Da (Figure 4.8.b). 
Additionally, IR spectral results show the presence of a broad peak from 3323 to 3498 cm-1 for 
compound 51 and a broad peak from 3078 to 3489 cm-1 for compound 52, both of which are consistent 
with the expected OH stretch from the new alcohol. 
 
Figure 4.7 
1
H NMR spectra for 3-halogenated-4-methoxybenzylalcohol compounds. a. 
1
H NMR spectrum for 3-
chloro-4-methoxybenzylalcohol. b. 
1
H NMR spectrum for 3-bromo-4-methoxybenzylalcohol. In each spectrum the 
labeled protons correspond with their respectively labeled peaks.  
 
Figure 4.8 GC/MS spectra for 3-halogenated-4-methoxybenzylalcohol compounds. a. GC/MS spectrum for 3-
chloro-4-methoxybenzyl alcohol. The M
+
 of this compound was found to be 172 Da with a (M+2)
+
 of 174 Da, both 
of which are consistent with the expected molecular weights of 172.03 and 174.03 Da. b. GC/MS spectrum for 3-
bromo-4-methoxybenzyl alcohol. The M
+
 of this compound was found to be 216 Da and the (M+2)
+
 was 218 Da, 
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both of which are consistent with the expected molecular weights of 215.98 and 217.98 Da. In both spectra the 
insert is added to emphasize the characteristic (M+2)
+
 peaks resulting from the chlorine and bromine atoms.  
  As with the previous two reactions, the chlorination using thionyl chloride (SOCl2) also worked 
very well, giving quantitative conversion of the alcohol to the benzyl chloride within  one hour, and 
isolated yields of 83 and 99 % for compounds 53 and 54, respectively. Evidence for the success of this 
reaction can be found in the 1H NMR spectra for these compounds (Figure 4.9 a and b),  both of which 
show a loss of the triplet peak, suggesting that the alcohol is no longer present. In addition to this, the 
methylene doublets for compounds 53 and 54, that were doublets due to their splitting by the OH 
proton are now singlets, suggesting that the alcohol has been replaced by a different functional group 
that does not contain any protons. Furthermore, GC/MS analysis of the products confirmed the addition 
of a chorine atom to the compound, resulting in a unique fragmentation pattern. This pattern included 
M+, (M+2)+, and (M+4)+ peaks for both compounds. For compound 53, the M+ was 190 Da, the (M+2)+ 
was 192 Da, and the (M+4)+ was 194 Da (Figure 4.10). These values were consistent with the expected 
values of 190.00, 191.99, and 193.99 Da, respectively. Similarly compound 54 displayed a M+ of 234 Da, 
an (M+2)+ of 236 Da, and an (M+4)+ of 238 Da, all of which are in agreement with the expected values of 
233.94, 235.94, and 237.94 Da, respectively (Figure 4.10).  
 
Figure 4.9 
1
H NMR spectra for 3-halogenated-4-methoxybenzylchloride compounds. a 
1
H NMR spectrum for 3-
chloro-4-methoxybenzylchloride. b. 
1
H NMR spectrum for 3-bromo-4-methoxybenzylchloride. In each spectrum 
the labeled protons correspond with their respectively labeled peaks. 
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Figure 4.10 GC/MS spectra for 3-halogenated-4-methoxybenzylchloride compounds. a. GC/MS spectrum for 3-
chloro-4-methoxybenzylchloride. The M
+
 for this compound was found to be 190 Da, with an (M+2)
+
 of 192 Da, 
and an (M+4)
+
 of 194 Da, all of which agree with the expected masses of 190.00, 191.99, and 193.99 Da. Figure 
4.10b. GC/MS spectrum for 3-bromo-4-methoxybenzylchloride. The M
+
 for this compound was found to be 234 Da, 
with an (M+2)
+
 of 236 Da, and an (M+4)
+
 of 238 Da, all of which are consistent with the expected molecular 
weights of 233.94, 235.94, and 237.94 Da. In both spectra the appearance of the (M+4)
+
 peak is in agreement with 
the addition of a chlorine atom to the compound resulting from chlorine's two abundant isotopes. The inserts in 
both spectra emphasize the complex M
+
, (M+2)
+
, and (M+4)
+
 fragmentation patterns for this compound.  
 The next reaction involved the use of an SN2 reaction between the cyanide anion and the 
halogenated benzyl chloride in order to form the requisite carbon-carbon bond, while simultaneously 
adding the necessary nitrogen. These reactions too, were fairly straightforward, as they were complete 
within an hour of adding NaCN and heating to 40 oC, giving excellent yields of 90 % for both compounds 
55 and 56. Although the 1H NMR spectra for these compounds are not significantly different than those 
of the benzylchloride compounds, it was still informative to see that the methylene peak had a large 
shift up field (proton A in Figure 4.11 a and b). For compound 53 this peak was found at 4.73 ppm, and 
was shifted to 3.95 ppm upon conversion to 55, while this peak shifted from 4.73 ppm to 3.93 ppm upon 
transformation from 54 to 56. In addition to this, mass spectral data for these products were also in 
agreement with what is expected for the desired compounds. Analysis of compound 55 resulted in an 
M+ of 181 Da, with an (M+2)+ of 183 Da, which were in agreement with the expected values of 181.03 
and 183.03 Da (Figure 4.12.a). Likewise analysis of compound 56 yielded an M+ of 225 Da and an (M+2)+ 
of 227 Da. These values are in agreement with the expected values of 224.98 and 226.98 Da (Figure 
4.12.b). In both cases, the appearance of odd molecular weights suggested that a single nitrogen atom 
was added to the molecules, further suggesting that the desired transformation was successful. Finally, 
IR spectroscopy for these compounds also suggests that a nitrile is present. The IR analysis of compound 
55 displays a peak from 2204 to 2299 cm-1, while compound 56 has a similar peak from 2208 to 2289 cm-
1, both of which are consistent with the expected CN triple bond stretch found in nitrile containing 
compounds, suggesting that the reaction was successful.  
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Figure 4.11 
1
H NMR spectra for 3-halogenated-4-methoxybenzylcyanide compounds. a 
1
H NMR spectrum for 3-
chloro-4-methoxybenzylcyanide. b. 
1
H NMR spectrum for 3-bromo-4-methoxybenzylcyanide. In each spectrum the 
labeled protons correspond with their respectively labeled peaks. 
 
Figure 4.12 GC/MS spectra for 3-halogenated-4-methoxybenzylcyanide compounds. a. GC/MS spectrum for 3-
chloro-4-methoxybenzylcyanide. GC/MS analysis of this compound yielded an M
+
 of 181 Da and an (M+2)
+
 of 183 
Da, both of which are consistent with the expected values of 181.03 and 183.03 Da. In addition to this, the odd 
molecular ions are also consistent with the incorporation of a single nitrogen atom into the molecule suggesting 
the desired transformation was successful. b. GC/MS spectrum for 3-bromo-4-methoxybenzylcyanide. The 
resulting M
+
 and (M+2)
+
 values were 225 Da and 227 Da respectively, and were in agreement with the expected 
values of 224.98 and 226.98 Da. Once again the odd molecular ions are in agreement with the incorporation of a 
single nitrogen atom into the molecule. In both spectra the insert shows a zoomed in picture of the molecular ions.  
 Once the halogenated benzylcyaindes were obtained, they were reduced to the desired 
phenethylamines by a simple reflux in a solution of BH3-THF complex, which gave the amines as free 
bases. These were then crystallized as their respective hydrobromide salts giving yields of 51 and 88 % 
for compounds 57 and 58, respectively. The 1H NMR spectra where very useful in determining the 
success of these reactions, since in both spectra there was a new broad peak that integrated to three 
protons, which is consistent with the production of a primary amine (proton A in Figure 4.13 a and b). 
For compound 57 this peak appeared at 7.75 ppm and for compound 58 this peak was found at 7.71 
ppm. The IR spectra for these compounds also show the loss of the nitrile peaks at about 2200 cm-1, 
showing that the nitrile starting material was successfully transformed into a different product. The IR 
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spectrum for compound 57 displayed three new peaks from 3196-3271, 3290-3445, and 3445-3533 cm-
1, which are consistent with what would be expected for the N-H stretches in a primary amine with three 
N-H bonds. The IR spectrum for compound 58, however, was not as well resolved and instead exhibited 
a single broad peak from 3202-3564 cm-1, which is within the expected range for the N-H stretch. The 
lack of resolution in this spectrum may indicate that the solvent or the compound may have had some 
residual water contamination, resulting in the broad peak. Based on these observations, it was 
determined that the two compounds were successfully synthesized.  
 
Figure 4.13 
1
H NMR spectra for 3-halogenated-4-methoxyphenethylamine compounds. a. 
1
H NMR Spectra for 3-
chloro-4-methoxyphenethylamine. b. 
1
H NMR spectra for 3-bromo-4-methoxyphenethylamine. In both cases the 
solvent is DMSO-d6 resulting in the solvent peak at 2.56 ppm. In Figure 4.13.a. the broad peak at 4.1 ppm is most 
likely the result of H3O
+
 present in the sample, while in Figure 4.13.b. the peak at 3.3 ppm is most likely due to 
water.  
 The final step to producing the desired 3-bromo and 3-chloro tyramine analogues was 
deprotection of the phenol. This reaction was also easily performed for compound 57 through an acid 
catalyzed SN2 type reaction, requiring only reflux of the compound in 48% HBr, followed by the removal 
of the solvent with a rotary evaporator, giving a yield of 88 % for compound 49. Analysis of the product 
by 1H-NMR spectroscopy confirms that the synthesis successfully yielded the desired 3-chlorotyramine. 
This can be seen by both the loss of the methoxy protons (proton G in Figure 4.13.a) and the appearance 
of a new singlet at 10.07 ppm (Proton G in Figure 4.14.a), which is consistent with what would be 
expected for the phenol proton.  Deprotection of 58, however, resulted in a significant side product that 
was roughly 33 % of the total product obtained by 1H NMR spectroscopy. This is evident through the 
analysis of the product by 1H NMR, which shows peaks that are consistent with the product, but also 
some new aromatic peaks as well (Figure 4.14.b). In addition to this, the amine signal (proton A in Figure 
4.14) displays an integration value of 4.46, which is about 50 % greater than the expected value of 3. The 
methylene peaks (protons B and C in Figure 4.14.b) also display greater than expected values of 3.36 and 
2.95, both of which are about 50 % greater than the expected value of 2. This suggests that the impurity 
is a second phenethylamine compound and there is a 2:1 ratio of the desired 3-bromotyramine to the 
undesired phenethylamine side product. Attempts to purify this compound by column chromatography 
did not yield a product of any greater purity, but instead resulted in a black oil. This suggests that the 
acid catalyzed deprotection of this compound is not suitable. Currently, we are exploring other 
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deprotection options that utilize less harsh conditions to mediate this reaction, including the use of 
Lewis acids such as BBr3 to catalyze this reaction at low temperatures.   
 
Figure 4.14 
1
H NMR spectra for 3-halogenated-4-hydroxyphenethylamine compounds. a. 
1
H NMR spectrum for 3-
chloro-4-hydroxyphenethylamine (3-chlorotyramine). b. 
1
H NMR spectrum for the mixture of products containing 
3-bromo-4-hydroxyphenethylamine (3-bromotyramine). The integrated peaks are the peaks that are consistent 
with what is expected for the desired compound. There also appears to be a major side product which is evident 
by the appearance of new aromatic peaks. In addition to this, the amine (proton A) and methylene (protons B and 
C) protons integrate to values approximately 50 % greater than their expected values suggesting that the side 
product is also a phenethylamine, and that there is a 2:1 ratio between the desired and undesired compounds.  
 
4.5 Summary 
 During the synthesis of 3-halogenated tyramines (49 and 50), two different synthetic routes 
were explored, both of which started with the respective 3-halo-4-hydroxybenzaldehyde (29 and 30). 
The first procedure started with a nitro-aldol reaction to yield the nitrostyrene products 47 and 48 in 
good yield, however, the subsequent reduction to yield the 3-halogenated tyramine 49 and 50 
compounds were unsuccessful. The alternative pathway tested started with compounds 29 and 30 as 
well. The phenol versions of these compounds were then protected by the addition of methyl groups 
using an SN2 reaction between the benzaldehyde starting materials and iodomethane, yielding the 3-
halo-4-methoxybenzaldehyde compounds (31 and 32). This protection was necessary for the success of 
the subsequent reduction, chlorination, cyanation, and nitrile reductions in order to yield the3-halo-4-
methoxyphenethylamine compounds (57 and 58). Deprotection of compound 57 was achieved through 
simple reflux in concentrated HBr. This yielded the target 3-chlorotyramine in 7 steps, with a cumulative 
yield of 4 %. Deprotection of 58 was not achieved in the same manner, and as such the synthesis of the 
target molecule 3-bromotyramine was not achieved. However, synthesis of the 4-methoxy-3-
bromophenethylamine precursor was achieved in 6 steps with an excellent cumulative yield of 51 %. 
This compound is one step away from yielding the desired compound, which maybe available through 
the use of Lewis acid mediated SN2 type reaction to yield the desired compound.   
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Chapter 5 Feeding Experiment Design and Proposed 
Work 
5.1 One-pot Synthesis/Feeding experiment of HPAA and Norcoclaurine Analogues 
 As previously stated, the synthesis of the various halogenated HPAA and norcoclaurine 
analogues was performed with the intention of utilizing them as precursors for halogenated berberine 
analogues. In order for this to be achieved, a method of feeding the compounds had to be developed. 
The general procedure that was utilized before, involved making a 1 mM solution of the analogue in a 
liquid solution of Gamborg's media, then filter sterilizing the solution, and suspending Berberis vulgaris 
(cell line PC-464) callus cell culture, purchased from the Leibiniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures (DSMZ), (Figure 5.1) in the resulting solution for one week with 
shaking.64 This method was previously shown to work in experiments involving fluorinated dopamine 
analogues and, it was hoped that the process could be adapted to become an extension of the NaOCl 
synthesis of HPAA analogues, and the one pot synthesis of norcoclaurine analogues.65 Since both of 
these reactions are performed utilizing benign reagents in a solution of phosphate buffer, it was hoped 
that the syntheses of halogenated HPAA and norcoclaurine analogues could be performed at 2 mM 
concentrations of HPAA using the procedures described in Chapter 2, then be quenched, and the 
solution diluted directly into an equal volume of doubly-concentrated Gamborg's media, filter sterilized, 
and the cells suspended and shaken. 
 
Figure 5.1. PC 464 cell line used for PDB of unnatural berberine analogues. Left plate of B. vulgaris callus cell 
culture. Liquid media cultures of B. Vulgaris cells used in feeding experiments.  
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 This was performed for each of the halogenated analogues of both HPAA and norcoclaurine by 
reacting a 2 mM solution of the respective tyrosine analogue with one equivalent of bleach until all of 
the halogenated tyrosine was consumed when monitored by HPLC. To this solution was added half an 
equivalent of ascorbic acid to promote a reducing environment in the solution, to quench any unreacted 
NaOCl, and to promote better stability of the products in solution. Ascorbic acid was chosen as the 
preservative of choice based on the results of two different reports that showed that ascorbic acid 
reduces the effects of salinity stress.66, 67 This type of stress was a concern because the syntheses were 
performed in a solution of sodium phosphate buffer that is of relatively high concentration (10 mM), 
which may have adverse effects on the health of the cells. In addition to this, ascorbic acid is necessary 
for plant health, as it increases the plant's ability to handle several other kinds of stresses including 
oxidative stress and damage from wounds and pathogens.68 Based on these observations, it seemed 
that the inclusion of this compound in cell media would serve three functions; quenching any unreacted 
NaOCl, stabilization of the catechol products from oxidation, and promotion of cell health. For the 
feeding of HPAA analogues, the resulting solution of ~2 mM analogue and 1 mM ascorbic acid was then 
filter sterilized into an equal volume of 2x Gamborg's media to yield a solution containing 1 mM 
analogue, 0.5 mM ascorbic acid, and 5 mM phosphate in a 1 x solution of Gamborg's media in which the 
PC-464 cells could be suspended and shaken. 
 This procedure was also adapted for the feeding of norcoclaurine analogues. This was 
performed using the same procedure for the preparation of HPAA and followed by an ascorbic acid 
quench yielding a solution containing 2 mM HPAA analogue and 1 mM ascorbic acid in 10 mM 
phosphate buffer. To the resulting solution, 1.2 equivalents of dopamine were added, and the reaction 
was allowed to proceed until all of the aldehyde was fully consumed. This resulted in a solution that was 
~ 2 mM norcoclaurine analogue, 1 mM ascorbic acid, and 10 mM phosphate (pH 7.0). This solution was 
then filter sterilized into an equal volume of 2x media yielding a final solution of 1 mM norcoclaurine 
analogue, 0.5 mM ascorbic acid, 5 mM phosphate, in 1x solution of Gamborg's media. A plate of PC-464 
cells were then suspended in the resulting analogue-media solutions for a week at room temperature 
while shaking, after which the solids were separated from the liquids, freeze dried, and then stored at -
80 oC, until they could be analyzed.  
 Currently, this procedure has been applied to the chlorinated and brominated HPAA and 
norcoclaurine analogues. The resulting cells and media were separated from each other by gravity 
filtration, and have been freeze dried, are currently stored at - 80 oC awaiting analysis. The proposed 
plan for analysis involves grinding the frozen cells and media in a solution of methanol in order to 
extract the organic soluble contents from the plant material and buffer salts. The liquid portion would 
then be filtered through a 0.22 µm filter and analyzed by high resolution LC/MS. The success of the 
incorporation of the analogues into the biosynthetic pathway would be determined through high 
resolution mass analysis of the extracted compounds. It is planned to look for the existence of all the 
possible intermediates in the biosynthesis of berberine as well as the final berberine product itself 
(Figure 5.2). If we find that the analogues are successfully incorporated into berberine biosynthetic 
pathway, then we hope to scale up the procedure and isolate the compound for future analysis. If it 
turns out that there is a buildup of an intermediate species, suggesting that the next enzyme in the 
pathway does not accept the analogue, we hope to develop mutant species of B. vulgaris that produce a 
mutant variety of the enzyme that might be able to incorporate our analogues. This analysis is currently 
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on hold until a collaboration between our group and a University or group that has access to a high 
resolution LC/MS, through which the samples could be run, is established. 
 
Figure 5.2. Predicted analogues that may result from PDB experiments of 3-halogenated HPAA and 3-
halogenated norcoclaurine analogues. When analyzing the LC/MS results of PDB, the predicted molecular weights 
of each the possible intermediate analogues would be looked for.  
5.2 Proposed Feeding Experiments of Tyramine Analogues 
 In addition to the feeding of berberine precursors, we also hope to feed tyramine analogues in 
order to produce unnatural galanthamine analogues. This would involve a very similar feeding 
procedure to that adopted for dopamine analogues previously used in our lab. A sample of cells would 
be suspended and shaken in a 1 mM solution of the respective halogenated tyramine analogue in 
Gamborg's media, for one week. Because galanthamine is volatile enough for GC analysis, GC/MS would 
be utilized as the initial verification of the success of the experiment. This would be followed up by a 
high resolution LC/MS analysis of the solution for confirmation, looking for all of the possible 
intermediate and product analogues (Figure 5.3). Unlike the data analysis of berberine analogues, the 
analysis of these data would be made more difficult because for each tyramine analogue there are two 
possible resulting galanthamine analogues (Figure 5.3).  If successful the hope is to scale up and isolate 
the galanthamine analogue for future experiments, and if the product does not successfully make it  
through the pathway, a mutant cell line would be developed. Currently these experiments are awaiting 
the successful development of callus cell culture for a Narcissus species, since all attempts to date have 
proven to be unsuccessful.  
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Figure 5.3: Predicted analogues that would arise from precursor directed biosynthesis of tyramine analogues. 
When analyzing the LC/MS results of PDB, the predicted molecular weights of each the possible intermediate 
analogues would be looked for. 
5.3 Summary 
 A one-pot synthesis/feeding experiment was developed and performed for the PDB of unnatural 
berberine analogues for the synthesis and feeding of HPAA and norcoclaurine analogues. To date this 
procedure has been performed on all of the chlorinated and brominated HPAA and norcoclaurine 
analogues, with the resultant cells currently awaiting LC/MS analysis. To date no feeding of unnatural 
tyramine analogues has been performed as we are currently waiting the development of callus cell 
culture for a Narcissus species. Once this cell culture is attained, we hope to develop a feeding 
experiment based off the description given, with the hopes of generating unnatural galanthamine 
analogues. 
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Appendix A Experimental Procedures 
 
General Procedures. All reagents were purchased from commercial suppliers at the highest available 
purity and used without further purification. Reactions were monitored using high pressure liquid 
chromatography on a Waters Acquity Ultra  Performance liquid chromatography instrument equipped 
with an Acquity UPLC BEH C18 (1.7  µm) 2.1x100 mm column or an Acquity UPLC BEH C18 (1.7 µm) 
2.1x50 mm column. The solvent conditions used for HPLC analysis are as follows Condition A: 0-70 % 
acetonitrile (ACN) in 0.1% trifluoroacetic acid (TFA) in MilliQ water over 10 minutes using the 2.1x100 
mm column. Condition B: 0-70 % ACN in 0.1 % TFA over 4.75, holding at 70 % ACN for 0.25 minutes using 
the 2.1x50 mm column. Condition C: 0-17.5% ACN in 0.1 % TFA over 2.5 minutes followed by 17.5% to 
70 % ACN in 0.1 % TFA over 1.5 minutes, holding at 70 % for 1 minutes using the 2.1x50 mm column. Gas 
Chromatography mass spectrometry analysis of products was performed using a Hewlett Packard 
HP6890 Gas Chromatography System with an Agilent Technologies 5975 inert mass selective detector. 
1H and 19F  NMR spectroscopy were performed using a Bruker Avance 300 MHz NMR spectrometer at  
300 MHz, and 282 MHz respectively. All 1H NMR peaks are described relative to a tetramethylsilane 
internal standard.  Infrared spectroscopy analysis of reaction products were performed using a ABB FT-
IR FTLA 2000 spectrometer. All reactions involving air or water sensitive reagents were performed using 
flame dried glassware under an inert atmosphere of N2. 
.   
 
 
3-iodo- 4-Hydroxyphenylacetic acid (14).38 To a stirring solution of 4-hydroxyphenylacetic acid (11) 
(1.527 g, 10 mmol) in 70 mL of methanol and  40 mL of concentrated NH4OH  was added I2 (5.712g, 22.5 
mmol) dissolved in ethanol  drop wise over 3 hours at 0°C. The reaction was allowed to stir for 1.5 more 
hours after which the solvent was removed under reduced pressure. The resulting solid was re-
suspended in acetone, filtered and the solvent removed under reduced pressure yielding 15 (30%) as a 
yellow solid. 1H NMR (300 MHz, Acetone-d6) δ 9.06 (s, 1H), 7.70 (d, J = 2.0 Hz, 1H), 7.18 (dd, J = 8.3, 2.1 
Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 3.54 (s, 2H).LRMS (EI+) M/z 278 (M+, 55.01) 233 (100) 152 (0.78) 106 
(14.7) 78 (9). HPLC retention time 2.52 mins condition B. Absorbance spectra λmax 229 nm minor λmax 284 
nm.  
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Methyl-2-(4-hydroxyphenyl) acetate(16).39 To a stirring solution of 4-hydroxyphenyl acetic acid (12) 
(1.569g 10.3 mmol) in methanol (60mL) was added concentrated H2SO4 (80 µL, cat.), and brought to 
reflux for 2 hours. The resulting solution was allowed to cool to room temp diluted with water and 
extracted into diethyl ether (3x20mL), and the combined organic layer washed with NaHCO3 (2x20mL), 
brine (1x20mL), dried over MgSO4 and the solvent removed under reduced pressure to yield 1.71g of 
(16) (92%)as a clear oil, which was stored in a freezer at -20oC. 1H NMR (300 MHz, Acetone d-6) δ 8.3 (s, 
1H), 7.15 (d, 2H), 6.75 (d, 2H), 3.65 (s, 3H), 3.53 (s, 2H). LRMS (EI+) M/z 166 (M+, 26.6), 107 (100), 77 
(14.6). HPLC retention time 6.86 mins condition A. Absorbance spectra λmax 222 nm minor λmax 281 nm.  
 
ethyl 2-(4-hydroxy-3-chlorophenyl)acetate (13).39  To a stirring solution of 3-chloro-4-hydroxyphenyl 
acetic acid (13) (0.5891 g, 3.14 mmol) in ethanol (50mL) was added concentrated H2SO4 (30 µL, cat.), and 
brought to reflux for 3 hours. The resulting solution was allowed to cool to room temp diluted with 
water and extracted into diethyl ether (3x20mL), and the organic layer washed with NaHCO3 (2x20mL), 
washed with a brine solution (1x20mL) and then dried with MgSO4. The solvent was then removed 
under reduced pressure to yield 0.636 of (59) (95%)as a clear oil, which was stored in a freezer at -20oC. 
1H NMR (300 MHz, Acetone-d6) δ 8.70 (s, 1H), 7.30 (d, J = 2.1 Hz, 1H), 7.10 (dd, J = 8.3, 2.1 Hz, 1H), 6.96 
(d, J = 8.3 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.56 (s, 2H), 1.22 (t, J = 7.1 Hz, 3H). LRMS (EI+) M/z 214 (M+, 
23.7), 216 (M+2, 7.8), 143 (32.9), 141 (100), 77 (17.3).  
 
2-iodo-4-(2-hydroxyethyl)phenol (23).40, 41 A solution containing 3-iodo-4-hydroxyphenylacetic acid (15) 
(0.1334g, 0.5 mmol) and trimethyl borane (114 µL, 1.0 mmol) in 1 mL THF was slowly added over 5 
minutes to an ice cold stirring solution of NaBH4 (0.0377g, 1 mmol) in 2 mL THF. Upon completion of this 
addition, dimethyl sulfate (93 µL, 1 mmol) was slowly added over 5 minutes and the resulting solution 
was allowed to stir over night at room temperature, after which the reaction was quenched by the 
addition of 3 mL of water. The resulting solution was then extracted into ethyl acetate (2X5 mL), the 
combined organic layers dried over MgSO4, and the solvent removed under reduced pressure, yielding 
0.022 g of (23) (17%) as an off white solid. 1H NMR (300 MHz, CDCl3) δ 8.86 (s, 1H), 7.61 (d, J = 2.1 Hz, 
1H), 7.10 (dd, J = 8.2, 2.1 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 3.73 – 3.65 (m, 3H), 2.70 (t, J = 6.6 Hz, 2H). 
LRMS (EI+) M/z 306 (M+, 60.6), 307 (M+1, 7.3), 248 (7.8), 247 (100), 105 (10.8), 91 (7.3), 90 (19.7), 77 
(14.6). HPLC retention time 2.48 mins condition B. Absorbance spectra λmax 217 nm minor λmax 284 nm. 
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4-(Methoxymethoxy)benzaldehyde (60).69 0.6106 g of 4-hydroxybenzaldehyde (44) (5 mmol) was 
dissolved in 30 mL of dry DMF (dried over 3 Å molecular Sieves) and in an oven dried 3 neck round 
bottom flask under a N2 atmosphere and cooled to 0 °C. To this solution 0.2106 g of NaH (60% 
dispersion in mineral oil) (5.1 mmol) was slowly added over 30 minutes. The solution was allowed to 
warm to room temperature and 0.39 mL of  chloromethoxymethyl ether (5.1 mmol)  was slowly added 
via syringe and stirred for 3 hours. The reaction was then quenched with water and stirred for 10 
minutes. The solvent was removed under reduced pressure  yielding a tan oil, which was purified using 
dry vacuum column chromatography (Hexanes/EtOAc -0-25%) yielding 0.5545 g of 64 as a clear oil 
(66.8%). 1H NMR (300 MHz, Acetone d-6) δ 9.91 (s, 1H), 7.85-7.95 (d, 2H), 7.17-7.28 (d, 2H), 5.29-5.40 (s, 
2H), 3.40-3.54 (s, 3H) LRMS (EI+) m/z 161 (M+, 100), 135 (47), 121 (9), 105 (22), 77 (52), 65 (35), 51 (35).  
 
 
(E)-1-methoxy-4-(2-methoxyvinyl)benzene(36).47, 48, 70 NaH (60% dispersion in mineral oil, 0.0818g, 2 
mmol) was added to a dry flask and washed with hexanes (2 x 10 mL) under N2 to remove the mineral 
oil. The resulting solid was suspended in 20 mL of sieve dried diethyl ether and 
methoxymethyltriphenylphosphonium chloride (0.7845 g, 2.3 mmol) was added slowly and brought to 
reflux for 30 minutes. The resulting solution was cooled to room temperature and 4-
methoxybenzaldehyde (33) was slowly added. The solution was brought back to reflux for 15 hr, then 
the reaction was then diluted with ether and quenched by washing with H2O (2 x 20mL). The organic 
layer was then washed once with 1 M HCl (1 x 20 mL) and once with brine (1 x 20 mL), then dried with 
MgSO4. The solvent was removed under reduced pressure yielding a yellow oil, which was not 
characterized. 
 
 
 
2-chloro-4-(2-hydroxyethyl)phenol (21).44 A suspension containing 4-(2-hydroxyethyl)phenol (20) 
(2.990, 21.6 mmol) and NaCl (1.266 g, 21.6 mmol)  in acetone (55 mL) was cooled to 0 oC while a 
solution of oxone (19.818 g, 32.2 mmol) in water (100 mL) was added drop wise over three hours. The 
reaction was then allowed to stir overnight at room temperature, after which the reaction was extracted 
with ethyl acetate (3 x 60 mL) and the combined organic layers washed with brine (1 x 30 mL). The 
resulting solution was then dried with MgSO4, filtered and the solvent removed under reduced pressure 
yielding an amber colored oil. The resulting oil was then dissolved in a minimal amount of hot 
dichloromethane and cooled yielding 3.735 g of 21 (72 %) as white crystals. 1H NMR (300 MHz, Acetone-
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d6) δ 8.64 (s, 1H), 7.39 (d, J = 2.0 Hz, 1H), 7.08 (dd, J = 8.2, 2.1 Hz, 1H), 6.94 – 6.88 (m, 1H), 3.73 – 3.70 
(m, 2H), 2.74 – 2.69 (m, 2H). LRMS (EI+)m/z 172 (M+, 25), 173 (M+1, 2,23), 174 (M+2, 8.4), 143 (33.2), 142 
(9.5), 141 (100), 107 (5.4), 105 (4.5), 77 (19.3). HPLC retention time 2.18 mins condition B. Absorbance 
spectra λmax 222 nm minor λmax 280 nm.  
 
2-bromo-4-(2-hydroxyethyl)phenol (22).44 A suspension containing 20 (3.463, 25 mmol) and NaBr (2.589 
g, 25.2 mmol) in acetone (55 mL) was cooled to 0 oC while a solution of oxone (23.153 g, 32.2 mmol) in 
water (100 mL) was added drop wise over three hours. The reaction was then allowed to stir for three 
additional hours at room temperature, after which the reaction was extracted with ethyl acetate (3 x 60 
mL) and the combined organic layers washed with brine (1 x 30 mL). The resulting solution was then 
dried with MgSO4, filtered and the solvent removed under reduced pressure yielding an amber colored 
oil. The resulting oil was then dissolved in a minimal amount of hot dichloromethane and cooled yielding 
4.292 g of 20 (79 %) as a white solid 1H NMR (300 MHz, Acetone D-6) δ 8.64 (s, 1H), 7.39 (d, J = 2.0 Hz, 
1H), 7.07 (dt, J = 8.1, 4.1 Hz, 1H), 6.95 – 6.89 (m, 1H), 3.72 (dd, J = 6.1, 4.4 Hz, 2H), 2.79 – 2.66 (m, 2H). 
LRMS (EI+)m/z 216 (M+, 23.8), 217 (M+1,2.4), 218 (M+2, 24.3 173 (16), 188 (9.0), 187 (97.9), 186 (9.1), 
185 (100), 107 (10) 106 (4.4) 78 (9.3), ( 77 (21.7). HPLC retention time 2.31 mins. Absorbance spectra 
λmax 218 nm minor λmax 281 nm.  
 
2-iodo-4-(2-hydroxyethyl)phenol (23).45 A solution of I2 (5.074 g, 20 mmol) and KI (4.374 g, 26 mmol) in 
100 mL of a 1:1 water and ethanol was added to a solution containing 4-(2-hydroxyethyl)phenol (20) 
(2.733 g, 20 mmol) dissolved in 20 mL of a 40% solution of dimethyl ammine. The resulting solution was 
allowed to stir at root temp for 4 hours after which it was acidified with a 2 M solution a HCl and 
extracted into ethyl acetate (3x100 mL). The combined organic layers were then washed with a 10% 
(m/V) solution of sodium thiosulfate (2x50 mL) and brine (1x40mL). The resulting organic layer was then 
dried with MgSO4, filtered, and the solvent removed under reduced pressure yielding a brown oil. The 
resulting oil was dissolved in a minimal amount of hot water and cooled yielding 3.7602 g of 20 (72 %) as 
white needle like crystals. 1H NMR (300 MHz, CDCl3) δ 7.55 (d, J = 2.0 Hz, 2H), 7.12 (dd, J = 8.2, 2.0 Hz, 
2H), 6.93 (d, J = 8.3 Hz, 2H), 5.40 (s, 2H), 3.84 (t, J = 6.5 Hz, 5H), 2.84 – 2.63 (m, 5H), 1.60 (d, J = 33.9 Hz, 
4H). LRMS (EI+)m/z 264 (M+ 35.2), 265 (M+1 3.0), 234 (9.8), 233 (100), 128 (1.4), 107 (5.0), 106 (13.9) 78 
(7.8), 77 (6.5). HPLC retention time 2.48 mins condition B. Absorbance spectra λmax 217 nm minor λmax 
284 nm.   
 
78 
 
 
2-fluoro-4-(2-hydroxyethyl)phenol (24).65 1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate (Selectfluor®) (0.4666g, 13 mmol) and 20 (0.16200g, 12 mmol) were dissolved in 
10 mL of a 1:1 methanol  water solution, and allowed to stir for 36 hours, after which, 0.2148 g of 
Selectfluor® was added and the reaction allowed to stir 12 more hours. The resulting solution was then 
diluted into 25 mL of water, and extracted into ethyl acetate (3x25mL), the combined organic layers 
were then washed with 25 mL of a brine solution, dried with MgSO4, filtered, and the solvent removed 
under reduced pressure, yielding 0.1771 g of an amber oil. 19FNMR analysis revealed several peaks 
suggesting that several fluorinated products were obtained. This was consistent with GCMS analysis, 
which suggested two different mono and difluorinated compounds were present.  
 
4-hydroxyphenylacetaldehyde (3).23-25, 43, 46 In a flame dried flask purged with N2, sulfur trioxide pyridine 
complex (3.1140 g, 20 mmol) was dissolved in 15 mL of sieve dried dimethyl sulfoxide. This solution was 
then canulated into a second flame dried flask purged with N2 containing 20(0.9513 g, 6.8 mmol) and 
triethyl amine (3 mL, 21 mmol), dissolved in 15 mL of sieve dried dimethyl sulfoxide, slowly over a period 
of 15 mins. The resulting solution was allowed to stir at room temperature for 1.5 hours under a N2 
atmosphere, after which it was poured into 100 mL of ice cold water and acidified with 10 mL of 2 M 
HCl. The resulting solution was extracted into ethyl acetate (3x100 mL), and the combined organic 
fractions washed with brine (2x100 mL), dried with MgSO4, filtered and the solvent removed under 
reduced pressure yielding a crude amber colored oil. The oil was purified by flash chromatography (20% 
ethyl acetate in hexanes) yielding 0.2272g of  3 (24%) as a clear oil. 1H NMR (300 MHz, CDCl3) δ 9.74 (t, J 
= 2.4 Hz, 1H), 7.15 – 7.06 (m, 2H), 6.90 – 6.82 (m, 2H), 4.80 (s, 1H), 3.63 (dd, J = 8.4, 2.9 Hz, 2H). LRMS 
(EI+)m/z 136 (M+ 17.6), 137 (M+1, 1.7), 108 (9.5), 107 (100), 89 (.63), 78 (3.7), 77 (21.6).  HPLC retention 
time 1.63 mins condition B. Absorbance spectra λmax 222 nm minor λmax 276 nm.  
 
3-chloro-4-hydroxyphenylacetaldehyde (25). In a flame dried flask purged with N2, sulfur trioxide 
pyridine complex (0.3110 g, 1.9 mmol) was dissolved in 5 mL of sieve dried dimethyl sulfoxide. This 
solution was then canulated into a second flame dried flask purged with N2 containing 20 (0.1289 g, 0.75 
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mmol) and triethyl amine (0.33 mL, 3.7 mmol), dissolved in 5 mL of sieve dried dimethyl sulfoxide, 
slowly over a period of 15 mins. The resulting solution was allowed to stir at room temperature for 4 
hours under a N2 atmosphere, after which it was poured into 100 mL of ice cold water. The resulting 
solution was extracted into ethyl acetate (3x50 mL), and the combined organic fractions washed with 
brine (1x40 mL), dried with MgSO4, filtered and the solvent removed under reduced pressure yielding a 
crude amber colored oil. Flash chromatography was performed (0-40% ethyl acetate in hexanes) yielding 
0.1274 g of 25 (35.5%). 1H NMR (300 MHz, CDCl3) δ 9.74 (t, J = 2.2 Hz, 1H), 7.20 (d, J = 6.4 Hz, 1H), 7.12 – 
7.01 (m, 2H), 5.62 (s, 1H), 3.66 (t, J = 11.0 Hz, 2H). LRMS (EI+)m/z 170 (M+, 5.89), 172 (M+2, 18.8), 143 
(32.2), 141 (100), 105 (5.4), 77 (25.6). HPLC retention time 2.17 mins condition B. Absorbance spectra 
λmax 222 nm minor λmax 280 nm.  
 
3-chloro-4-hydroxyphenylacetaldehyde (26). In a flame dried flask purged with N2, sulfur trioxide 
pyridine complex (0.897 g, 5.6 mmol) was dissolved in 10 mL of sieve dried dimethyl sulfoxide. This 
solution was then canulated into a second flame dried flask purged with N2 containing 20 (0.5858 g, 2.7 
mmol) and triethyl amine (0.75 mL, 5.4 mmol), dissolved in 10 mL of sieve dried dimethyl sulfoxide, 
slowly over a period of 15 mins. The resulting solution was allowed to stir at room temperature for 1 
hour under a N2 atmosphere, after which it was poured into 150 mL of ice cold water. The resulting 
solution was extracted into ethyl acetate (3x75 mL), and the combined organic fractions washed with 
brine (1x50 mL), dried with MgSO4, filtered and the solvent removed under reduced pressure yielding a 
crude orange oil. Flash chromatography was performed (25% ethyl acetate in hexanes) yielding 0.0361 g 
of 20 (6.2%). 1H NMR (300 MHz, CDCl3) δ 9.72 (d, J = 16.0 Hz, 1H), 7.35 (s, 1H), 7.09 (d, J = 8.5 Hz, 1H), 
7.03 (d, J = 8.3 Hz, 1H), 5.61 (s, 1H), 3.61 (d, J = 22.4 Hz, 2H). LRMS (EI+) m/z 214 (M+, 17.4), 215 (M+1, 
2.5), 216 (M+2, 18.0), 188 (8.7), 187 (100), 186 (9.7), 185 (97), 107 (6.1), 106 (4.9), 78 (15.6), 77 (26). 
HPLC retention time 2.33 mins condition B. Absorbance spectra λmax 223 nm minor λmax 281 nm.  
 
3-iodo-4-hydroxyphenylacetaldehyde(27). In a flame dried flask purged with N2, sulfur trioxide pyridine 
complex (0.869 g, 5.5 mmol) was dissolved in 10 mL of sieve dried dimethyl sulfoxide. This solution was 
then canulated into a second flame dried flask purged with N2 containing 23 (0.7060 g, 2.7 mmol) and 
triethyl amine (0.75 mL, 5.4 mmol), dissolved in 10 mL of sieve dried dimethyl sulfoxide, slowly over a 
period of 15 mins. The resulting solution was allowed to stir at room temperature for 1 hour under a N2 
atmosphere, after which it was poured into 100 mL of ice cold water. The resulting solution was 
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extracted into ethyl acetate (3x80 mL), and the combined organic fractions washed with brine (1x100 
mL), dried with MgSO4, filtered and the solvent removed under reduced pressure yielding a crude 
orange oil. Flash chromatography was performed (30% ethyl acetate in hexanes) yielding 0.1804 g of 27 
(26%) as a slightly colored oil. 1H NMR (300 MHz, CDCl3) δ 9.74 (t, J = 2.2 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 
7.12 (dd, J = 8.3, 2.1 Hz, 1H), 7.01 (d, J = 8.3 Hz, 1H), 5.29 (s, 1H), 3.63 (d, J = 2.2 Hz, 2H). LRMS (EI+) 262 
(M+, 26.6), 263 (M+1, 2.2), 234 (8.4), 233 (100), 136 (0.19), 127 (2.41), 107 (3.5), 106 (16.5), 78 (10), 77 
(9). HPLC retention time 2.63 mins condition B. Absorbance spectra λmax 284 nm.  
 
3-chloro-tyrosine(41).32 Tyrosine (7.567 g, 41.8 mmol) was suspended in 75 mL of glacial acetic acid and 
SO2Cl2 (3.44 mL, 44 mmol)was slowly added to the suspension over 10 minutes. The resulting solution 
was allowed to stir for 5.5 hours, after which the solid precipitate was collected by vacuum filtration and 
washed with glacial acetic acid (3x10 mL) and diethyl ether (3x25mL). The resulting product was then 
recrystallized from boiling concentrated hydrochloric acid yielding 6.910 g of 41 (66%) as the white 
crystals. 1H NMR (300 MHz, DMSO-d6) δ 10.17 (s, 1H), 8.25 (s, 3H), 7.24 (d, J = 2.0 Hz, 1H), 7.02 (dd, J = 
8.3, 2.1 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 4.14 (s, 1H), 3.00 (t, J = 5.7 Hz, 2H). HPLC retention time 1.56 
mins condition B. Absorbance spectra λmax 222 nm minor λmax 280 nm.  
 
 
3-bromotyrosine(42).33 A solution containing 1 (5.541 g, 30.6 mmol) suspend in 25 mL of glacial acetic 
acid and 15 mL of a 33% solution of HBr in acetic acid (61 mmol), was prepared. A solution of Bromine 
(1.7 mL, 33.2 mmol) in 25 mL of glacial acetic acid was then added to the previously prepared solution 
over a period of 3 hours, and the resulting solution was allowed to stir for 24 hours. Upon completion of 
the reaction the solid precipitate was collected by vacuum filtration, washed with glacial acetic acid 
(3x25 mL) and diethyl ether (3x25mL) yielding an orange powder. The powder was recrystallized from 
boiling concentrated hydrochloric acid yielding 6.023g of 42 (70%) as white crystals. 1H NMR (300 MHz, 
D2O) δ 7.40 (d, J = 2.1 Hz, 1H), 7.06 (dd, J = 8.3, 2.1 Hz, 1H), 6.89 (d, J = 8.3 Hz, 1H), 4.12 (d, J = 5.4 Hz, 
1H), 3.15 (dd, J = 14.7, 5.6 Hz, 1H), 3.02 (dd, J = 14.8, 7.6 Hz, 1H). HPLC retention time 1.64 mins 
condition B. Absorbance spectra λmax 280 nm.  
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3-iodotyrosine(43).34 A solution of 1 (4.968 g, 27 mmol) dissolved in concentrated NH4OH was cooled in 
an ice water bath, and iodine (7.0325 g, 27.8 mmol)dissolved in 150 mL of ethanol was slowly added 
dropwise via syringe pump. The resulting solution was allowed to stir overnight, after which the solvent 
was removed under reduced pressure, yielding an off white solid, which was suspended in 150 mL of ice 
cold water. The solid was collected by vacuum filtration and re-suspended in ice cold acetone and 
stirred for 1.5 hours. The resulting solid was collected by vacuum filtration yielding 2.528 g of 43 (30 %) 
as a white powder. 1H NMR (300 MHz, D2O) δ 7.60 (d, J = 2.1 Hz, 1H), 7.12 – 7.03 (m, 1H), 6.83 (d, J = 8.3 
Hz, 1H), 3.84 – 3.78 (m, 1H), 3.10 – 3.01 (m, 1H), 2.91 (dd, J = 14.7, 7.8 Hz, 1H). HPLC retention time 1.78 
mins condition B. Absorbance spectra λmax 283 nm.  
Standardization of sodium thiosulfate.52 A solution of sodium thiosulfate containing 0.025 g NaCO3 as a 
preservative was standardized against a 0.03740 M solution of KIO3 by dissolving approximately 2 g of 
potassium iodide in 5 mL of 6 M H2SO4 and 10 mL of the KIO3 solution. The resulting solution was 
titrated with the sodium thiosulfate solution until it was a pale yellow solution, after which a mL of a 
starch indicator solution was added. The resulting blue solution was then titrated until the solution was 
clear. The above procedure was repeated 4 times yielding a concentration of (5.14 ±0.05) x 10-2 M.  
Titration of a 10-15% NaOCl.52 2.4476 g of a 10-15% solution of sodium hypochlorite was diluted into a 
250 mL volumetric flask with Milli Q water. 50 mL of the resulting solution was then added to a flask, 
and diluted with 50 mL of Milli Q water. To this solution, 10 mL of glacial acetic acid and approximately 2 
g of KI were added and mixed thoroughly, yielding a brown solution, which was titrated with a (5.14 
±0.05) x 10-2 M solution of Na2S2O3 until pale yellow, after which 1 mL of a starch indicator was added. 
The resulting blue solution was then titrated until the solution became clear. This was repeated 3 times 
yielding a concentration of 9.16% by mass NaOCl . 
 
4-hydroxyphenylacetaldehyde(3).26, 50 A solution of 1 (0.189 g, 1 mmol) in 250 mL of 10 mM phosphate 
pH 7, was warmed in a 37 oC warm room. To this, a solution containing 730 uL of 9.16 % NaOCl (1 molar 
equivalent) dissolved in 7 mL of Milli Q water was added drop wise over 7 mins via syringe pump with 
vigorous stirring. This solution was allowed to stir at 37 oC for 2 hours. The resulting solution was 
extracted into ethyl acetate (3x100 mL), dried over MgSO4, filtered, and the solvent removed under 
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reduced pressure yielding 0.0938 g of 3 (66 %) as a brown oil. 1H NMR (300 MHz, CDCl3) δ 9.74 (t, J = 2.4 
Hz, 1H), 7.11 (d, J = 8.5 Hz, 2H), 6.89 – 6.82 (m, 2H), 4.75 (s, 1H), 3.64 (d, J = 2.3 Hz, 2H). LRMS (EI+)m/z 
136 (M+ 17.6), 137 (M+1, 1.7), 108 (9.5), 107 (100), 89 (.63), 78 (3.7), 77 (21.6). HPLC retention time 1.63 
mins condition B. Absorbance spectra λmax 222 nm minor λmax 276 nm.     
 
3-chloro-4-hydroxyphenylacetaldehyde(25). A solution of 41 (0.253g, 1 mmol) ) in 250 mL of 10 mM 
phosphate pH 7, was warmed in a 37 oC warm room. To this, a solution containing 70 uL of 9.16 % NaOCl 
(1 molar equivalent) dissolved in 7 mL of Milli Q water was added drop wise over 7 mins via syringe 
pump with vigorous stirring. This solution was allowed to stir at 37 oC for 1.5 hours. The resulting 
solution was extracted into CH2Cl2(3x100 mL), dried over MgSO4, filtered, and the solvent removed 
under reduced pressure yielding 0.1426 g of 25 (83 %) as a brown oil. 1H NMR (300 MHz, CDCl3) δ 9.75 (t, 
J = 2.1 Hz, 1H), 7.21 (s, 1H), 7.04 (s, 2H), 5.55 (s, 1H), 3.64 (d, J = 2.1 Hz, 2H). LRMS (EI+)m/z 170 (M+, 
5.89), 172 (M+2, 18.8), 143 (32.2), 141 (100), 105 (5.4), 77 (25.6). HPLC retention time 2.17 mins 
condition B. Absorbance spectra λmax 222 nm minor λmax 280 nm.  
 
3-bromo-4-hydroxyphenylacetaldehyde(26). A solution of 42 (0.298g, 1 mmol) ) in 250 mL of 10 mM 
phosphate pH 7, was warmed in a 37 oC warm room. To this, a solution containing 700 uL of 9.16 % 
NaOCl (1 molar equivalent) dissolved in 7 mL of Milli Q water was added drop wise over 7 mins via 
syringe pump with vigorous stirring. This solution was allowed to stir at 37 oC for 1.5 hours. The resulting 
solution was extracted into CH2Cl2 (3x100 mL), dried over MgSO4, filtered, and the solvent removed 
under reduced pressure yielding 0.177 g of 26 (82 %) as a brown oil. 1H NMR (300 MHz, CDCl3) δ 9.74 (t, 
J = 2.1 Hz, 1H), 7.35 (t, J = 2.7 Hz, 1H), 7.09 (dd, J = 8.3, 1.8 Hz, 1H), 7.03 (d, J = 8.3 Hz, 1H), 5.58 (s, 1H), 
3.64 (d, J = 2.0 Hz, 2H). LRMS (EI+) m/z 214 (M+, 17.4), 215 (M+1, 2.5), 216 (M+2, 18.0), 188 (8.7), 187 
(100), 186 (9.7), 185 (97), 107 (6.1), 106 (4.9), 78 (15.6), 77 (26). HPLC retention time 2.33 mins 
condition B. Absorbance spectra λmax 223 nm minor λmax 281 nm.   
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3-iodo-4-hydroxyphenylacetaldehyde (27). A solution of 43 (0.302 g, 1 mmol) ) in 250 mL of 10 mM 
phosphate pH 7, was warmed in a 37 oC warm room. To this, a solution containing 700 uL of 9.16 % 
NaOCl (1 molar equivalent) dissolved in 7 mL of Milli Q water was added drop wise over 7 mins via 
syringe pump with vigorous stirring. This solution was allowed to stir at 37 oC for 1.5 hours. The resulting 
solution was extracted into CH2Cl2 (3x200 mL), dried over MgSO4, filtered, and the solvent removed 
under reduced pressure yielding 0.160 g of 27 (62 %) as a brown oil. 1H NMR (300 MHz, CDCl3) δ 9.74 (t, 
J = 2.2 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.11 (dd, J = 8.3, 2.1 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1H), 5.36 (s, 1H), 
3.63 (t, J = 3.2 Hz, 2H). LRMS (EI+) 262 (M+, 26.6), 263 (M+1, 2.2), 234 (8.4), 233 (100), 136 (0.19), 127 
(2.41), 107 (3.5), 106 (16.5), 78 (10), 77 (9). HPLC retention time 2.63 mins condition B. Absorbance 
spectra λmax 284 nm.   
 
Norcoclaurine(4).25, 26, 50  A solution of 3 was generated by dissolving  1 (0.189 g, 1 mmol) in 250 mL of 20 
mM phosphate pH 7, was warmed in a 37 oC warm room. To this, a solution containing 700 uL of 9.16 % 
NaOCl (1 molar equivalent) dissolved in 20 mL of Milli Q water was added drop wise over 20 mins via 
syringe pump with vigorous stirring. This solution was allowed to stir at 37 oC for 2 hours, and quenched 
by the addition of ascorbic acid (0.185 g, 1 mmol). Dopamine hydrochloride (2) (0.2913g, 1.5 mmol) was 
added to the resulting solution, which was stirred until all of the aldehyde was consumed as monitored 
by HPLC (condition B). The reaction was then extracted into ethyl acetate (3x250 mL), dried with MgSO4, 
and the solvent removed under reduced pressure yielding 0.0804 g of 4 (28%) as a yellow solid. 1H NMR 
(300 MHz, Methanol-d4) δ 7.10 (d, J = 8.5 Hz, 2H), 6.77 (d, J = 8.5 Hz, 2H), 6.66 (s, 1H), 6.53 (s, 1H), 3.18 
(s, 2H), 2.84 (s, 2H), 2.69 (s, 2H), 2.02 (d, J = 2.9 Hz, 1H).  HPLC retention time 1.74 mins condition B. 
Absorbance spectra λmax 225 nm minor λmax 283 nm.    
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3-chloronorcoclaurine(44). A solution of 25 was generated by dissolving 41 (0.3098, 1.5 mmol) in 500 
mL of 20 mM phosphate solution pH 7 was warmed in a 37 oC warm room . To this, a solution containing 
1050 µL of 9.16 % NaOCl (1 molar equivalent) dissolved in 40 mL of Milli Q water was added drop wise 
over 40 mins via syringe pump with vigorous stirring. This solution was allowed to stir at 37 oC for 2 
hours, and quenched by the addition of ascorbic acid (0.161 g, 0.9 mmol). 2 (0.295g, 1.5 mmol) was 
added to the resulting solution, which was stirred until all of the aldehyde was consumed as monitored 
by HPLC (condition B). The reaction was then extracted into ethyl acetate (3x250 mL), dried with MgSO4, 
and the solvent removed under reduced pressure yielding 0.1955 g of 44 (45%) as a yellow solid. 1H 
NMR (300 MHz, CDCl3) δ 7.25 (d, J = 2.1 Hz, 1H), 7.07 – 7.02 (m, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.64 (s, 1H), 
6.56 (s, 1H), 3.29 – 3.16 (m, 3H), 2.98 (d, J = 6.7 Hz, 1H), 2.87 – 2.74 (m, 3H). HPLC retention time 1.98 
mins condition B. Absorbance spectra λmax 284 nm. 
 
3-bromonorcoclaurine(45). A solution of 26 was generated by dissolving 42 (0.5235, 2 mmol) in 500 mL 
of 20 mM phosphate solution pH 7 was warmed in a 37 oC warm room . To this, a solution containing 
1400 µL of 9.16 % NaOCl (1 molar equivalent) dissolved in 20 mL of Milli Q water was added drop wise 
over 20 mins via syringe pump with vigorous stirring. This solution was allowed to stir at 37 oC for 2 
hours, and quenched by the addition of ascorbic acid (0.2100 g, 1.2 mmol). 2 (0.381 g, 2 mmol) was 
added to the resulting solution, which was stirred until all of the aldehyde was consumed as monitored 
by HPLC (condition B). The reaction was then extracted into ethyl acetate (3x250 mL), dried with MgSO4, 
and the solvent removed under reduced pressure yielding 0.3391 g of 45 (48%) as a tan solid. 1H NMR 
(300 MHz, CDCl3) δ 10.20 – 9.87 (m, 1H), 8.73 (s, 1H), 8.68 – 8.50 (m, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.11 – 
7.01 (m, 1H), 6.87 (d, J = 8.2 Hz, 1H), 6.60 (s, 1H), 6.43 (s, 1H), 3.98 – 3.92 (m, 1H), 3.09 – 3.03 (m, 1H), 
2.94 (s, 1H), 2.80 – 2.73 (m, 1H), 2.67 (d, J = 13.9 Hz, 1H). HPLC retention time 2.05 mins condition B. 
Absorbance spectra λmax 284 nm.  
 
3-iodonorcoclaurine(46). A solution of 27 was generated by dissolving 46 (0.1650, 0.53 mmol) in 250 mL 
of 20 mM phosphate solution pH 7 was warmed in a 37 oC warm room . To this, a solution containing 
375 µL of 9.16 % NaOCl (1 molar equivalent) dissolved in 5 mL of Milli Q water was added drop wise over 
5 mins via syringe pump with vigorous stirring. This solution was allowed to stir at 37 oC for 2 hours, and 
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quenched by the addition of ascorbic acid (0.0949 g, 0.54 mmol). 2 (0.101 g, 0.54 mmol) was added to 
the resulting solution, which was stirred until all of the aldehyde was consumed as monitored by HPLC 
(condition B). The reaction was then extracted into ethyl acetate (3x250 mL), dried with MgSO4, and the 
solvent removed under reduced pressure yielding 0.1179 g of 46 (55%) as a yellow solid. 1H NMR (300 
MHz, Methanol-D4 ) δ 7.64 (d, J = 2.0 Hz, 1H), 7.13 – 7.07 (m, 1H), 6.82 (d, J = 8.2 Hz, 1H), 6.64 (s, 1H), 
6.55 (s, 1H), 3.24 – 3.13 (m, 2H), 2.93 (d, J = 7.3 Hz, 1H), 2.83 – 2.68 (m, 3H), 2.03 (s, 1H). HPLC retention 
time 2.21 mins condition B. Absorbance spectra λmax 285 nm.  
 
 
3-chloro-4-hydroxybenzaldehyde(29).32 4-hydroxybenzaldehyde (28) (3.130 g, 25.6 mmol) was 
5dissolved in 25 mL of glacial acetic acid and SO2Cl2 (3.82 g, 27.5 mmol) was added all in one portion. 
The resulting solution was allowed to stir at room temperature for 4 hours, and the resulting precipitate 
was collected by vacuum filtration. The collected solid was then allowed to dry under vacuum over 
night, then recrystallized from boiling water yielding 2.419 g of 29 (61%) as white needle like crystals. 1H 
NMR (300 MHz, CDCl3) δ 9.87 (s, 1H), 7.92 (d, J = 1.9 Hz, 1H), 7.76 (dd, J = 8.4, 1.9 Hz, 1H), 7.18 (d, J = 8.4 
Hz, 1H), 6.17 (s, 1H). ). LRMS (EI+)m/z 156 (M+,70.0), 157 (M+1, 38.5), 158 (M+2, 20.94), 155 (100), 129 
(6.4), 127 (18.7), 101 (5.9), 99 (19.1), 91 (5.9), 77 (0.42).  HPLC retention time 2.538 mins condition B. 
Absorbance spectra λmax 228 nm minor λmax 275 nm.  
 
3-bromo-4-methoxybenzaldehyde(30).37 A solution containing 28 (3.147 g, 25.8 mmol) and p-
toluenesulfonic acid (2.309 g, 12.1 mmol) in 120 mL of acetonitrile was allowed to stir for 5 minutes 
after which, N-bromosuccinimide (4.946 g, 27.8 mmol) was added and the resulting solution was then 
allowed to stir over night at room temperature. The product was then extracted into diethyl ether 
(3x100 mL), washed with 10 % sodium thiosulfate (1x100 mL), washed with brine (1x100 mL), dried over 
MgSO4, filtered, and the solvent removed under reduced pressure. The resulting solid was recrystallized 
from water yielding 4.428 g of 30 (86 %) as off white needle like crystals. 1H NMR (300 MHz, Acetone-d6) 
δ 9.86 (s, 1H), 8.09 (t, J = 2.8 Hz, 1H), 7.84 – 7.76 (m, 1H), 7.20 (d, J = 8.4 Hz, 1H). LRMS (EI+)m/z 200 
(M+,55), 201 (M+1, 90), 202 (M+2,60), 203 (M+3, 6.8), 199 (100), 173 (16), 171 (14), 145 (11), 143 (11), 
119 (4.6), 92 (19), 79 (2.1). HPLC retention time 2.69 mins condition B. Absorbance spectra λmax 229 nm 
minor λmax 286 nm.  
86 
 
 
3-chloro-4-methoxynitrostyrene(47).71 A solution containing (29) (1.254 g, 8.0 mmol) and ammonium 
acetate (0.413 g, 5.4 mmol) in 50 mL nitromethane was allowed to reflux for 6 hours. The resulting red 
solution was then poured into 200 mL of water, extracted into diethyl ether (3x150 mL), washed with 
brine (1 x 150 mL), dried over MgSO4, filtered and the solvent removed under reduced pressure, yielding 
1.508 g of 47 (94%) as a red solid. 1H NMR (300 MHz, CDCl3) δ 7.97 – 7.88 (s, 1H), 7.58 (d, J = 2.1 Hz, 1H), 
7.52 (d, J = 13.6 Hz, 1H), 7.43 (dd, J = 8.6, 2.1 Hz, 1H), 7.12 (d, J = 8.5 Hz, 1H), 5.99 (s, 1H). HPLC retention 
time 3.30 mins condition B. Absorbance spectra λmax 246 nm minor λmax 354 nm.   
 
3-bromo-4-methoxynitrostyrene(48).71 A solution containing (30) (1.656 g, 8.2 mmol) and ammonium 
acetate (0.950 g, 12.3 mmol) in 50 mL nitromethane was allowed to reflux overnight. The resulting red 
solution was then poured into 150 mL of water, extracted into diethyl ether (3x150 mL), washed with 
brine (1 x 100 mL), dried over MgSO4, filtered and the solvent removed under reduced pressure, yielding 
1.885 g of 48 (94%) as a red solid. 1H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 13.6 Hz, 1H), 7.72 (d, J = 2.1 Hz, 
1H), 7.53 (t, J = 9.5 Hz, 1H), 7.47 (dd, J = 8.5, 2.1 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H), 5.94 (s, 1H). HPLC 
retention time 3.37 mins condition B. Absorbance spectra λmax 250 nm minor λmax 355 nm.   
 
3-chloro-4-hydroxyphenethylamine(52).62 47 (0.205 g, 1 mmol) and Zn dust (0.503 g, 7.7 mmol) were 
slowly added in alternating portions over the course of 1.5 hours to a solution of 1 mL concentrated HCl 
in 2 mL of methanol at 0 oC. The resulting solution was then incubated at 4 oC and allowed to stir 
overnight, yielding a thick gray paste that showed several peaks by when monitored by HPLC suggesting 
that the reaction was not successful.  
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3-chloro-4-methoxybenzaldehyde(31).72 A solution of tetrabutylammonium hydrogen sulfate (1.147 g, 
3.4 mmol) in 50 mL of 2 M NaOH was added to a solution of 29 (0.935 g, 6.0 mmol) in 30 mL of CH2Cl2 
while stirring. After the solution became clear, methyl iodide (4.3 mL, 69 mmol) was added and the 
resulting solution was allowed to stir for 24 hours. The solution was then neutralized through the 
addition of 25 mL of 6 M HCl, and the organic phase was separated from the aqueous. The aqueous 
phase was then extracted with DCM (3x50 mL) and  the combined organic fractions washed with brine 
(1x40 mL), dried with MgSO4, filtered, and the solvent removed under reduced pressure. The resulting 
crude oil was  then purified through flash column chromatography (20% ethyl acetate in hexanes) to 
yield 0.572 g of 29 (79%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 9.90 (d, J = 9.5 Hz, 1H), 7.94 (d, J = 
2.0 Hz, 1H), 7.80 (dd, J = 8.5, 2.0 Hz, 1H), 7.07 (d, J = 8.5 Hz, 1H), 4.02 (s, 3H). LRMS (EI+)m/z 170 
(M+,64.1), 171 (M+1, 37.6), 172 (M+2, 21.4), 173 (M+3, 1.8) 169 (100), 154 (1.0), 141 (8.1), 126 (9.3), 111 
(6.3), 99 (13.0), 77 (9.6).   HPLC retention time 3.50 mins condition B. Absorbance spectra λmax 226 nm 
minor λmax 274 nm.   
 
 
3-bromo-4-methoxybenzaldehyde(32).72 A solution of tetrabutylammonium hydrogen sulfate (3.252 g, 
9.6 mmol) in 140 mL of 2 M NaOH was added to a solution of 30 (3.514 g, 17.5 mmol) in 120 mL of 
CH2Cl2 while stirring. After the solution became clear, methyl iodide (11.5 mL, 122 mmol) was added and 
the resulting solution was allowed to stir for 24 hours. The solution was then neutralized through the 
addition of 50 mL of 6 M HCl, and the organic phase was separated from the aqueous. The aqueous 
phase was then extracted with DCM (2X150 mL) and  the combined organic dried with MgSO4, filtered, 
and the solvent removed under reduced pressure. The resulting crude oil was  then purified through dry 
vacuum column chromatography (50% ethyl acetate in hexanes) to yield 3.678 g of 30 (98 %) as a white 
solid. 1H NMR (300 MHz, CDCl3) δ 9.87 (s, 1H), 8.11 (d, J = 2.0 Hz, 1H), 7.85 (dd, J = 8.5, 2.0 Hz, 1H), 7.04 
(d, J = 8.5 Hz, 1H), 4.00 (d, J = 8.6 Hz, 3H). LRMS (EI+)m/z 214 (M+,74.5), 216 (M+2, 73.6), 217 (M+3, 6.3), 
215 (100) 213 (96.2), 187 (6.9), 185 (7.3), 172 (8.7), 170 (8.4), 157 (6.8), 155 (6.0), 145 (10.7), 143 (11.4), 
119 (7.9), 104 (3.4), 77 (8.7). HPLC retention time 3.60 mins condition B. Absorbance spectra λmax 229 
nm minor λmax 275 nm.   
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4-methoxybenzylalcohol(61).63 Sodium borohydride (0.131 g, 3.5 mmol) was added in one portion to a 
solution containing 33 (0.7106 g, 5.2 mmol) and the resulting solution was allowed to stir overnight. The 
reaction was then quenched by the addition of 4 mL of acetone and the solvent was removed under 
reduced pressure. The resulting oily residue was then dissolved in 50 mL of CH2Cl2 and the organic 
solution washed with water (2x15 mL). The organic solution was then dried with MgSO4, filtered through 
a celite plug, and the solvent removed under reduced pressure yielding 0.458 g of 61 (64%) as a yellow 
oil that crystallized at -20 oC. 1H NMR (300 MHz, CDCl3) δ 7.31 (t, J = 7.2 Hz, 2H), 6.95 – 6.86 (m, 2H), 4.65 
(d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 1.55 (t, J = 5.9 Hz, 1H). ). LRMS (EI+)m/z 138 (M+,100), 139 (M+1, 8.7), 137 
(69) 123 (6.2), 121 (52), 109(73), 107(27), 105 (14.3), 94 (35), 91 (9.5), 79 (18.4), 77 (46). HPLC retention 
time 2.18 mins condition B. Absorbance spectra λmax 225 nm minor λmax 274 nm.    
 
3-chloro-4-methoxybenzylalcohol(51).63 Sodium borohydride (0.101 g, 2.8 mmol) was added in one 
portion to a solution containing 31 (0.551 g, 3.2 mmol) and the resulting solution was allowed to stir 
overnight. The reaction was then quenched by the addition of 8 mL of acetone and the solvent was 
removed under reduced pressure. The resulting oily residue was then dissolved in 75 mL of CH2Cl2 and 
the organic solution washed with brine (2x50 mL). The combined brine layers were then washed with 75 
mL of CH2Cl2 and the combined organic phase was then dried with MgSO4, filtered through a celite plug, 
and the solvent removed under reduced pressure yielding 0.689 g of 51 (120%) as a clear oil that 
crystallized at -20 oC. 1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 2.1 Hz, 1H), 7.24 (dd, J = 8.4, 2.1 Hz, 1H), 
6.93 (d, J = 8.4 Hz, 1H), 4.63 (d, J = 5.3 Hz, 2H), 3.92 (s, 3H), 1.66 (t, J = 5.7 Hz, 1H). LRMS (EI+)m/z 172 
(M+,100), 173 (M+1,18), 174 (M+2, 33) 171(35), 169 (19), 157(13), 155(33), 143(49), 141 (23), 139 (6.2), 
132 (54), 128 (13), 113 (9.1), 108 (36), 107 (23), 105 (8.3), 94 (13.9), 77 (46.4). HPLC retention time 2.70 
mins condition B. Absorbance spectra λmax 228 nm minor λmax 278 nm.     
 
3-bromo-4-methoxybenzylalcohol(52).63 Sodium borohydride (0.458 g, 12 mmol) was added in one 
portion to a solution containing 32 (3.6783 g, 17 mmol) and the resulting solution was allowed to stir 
overnight. The reaction was then quenched by the addition of 30 mL of acetone and the solvent was 
removed under reduced pressure. The resulting oily residue was then dissolved in 70 mL of water and 
then acidified with 2 M HCl. The water was then extracted with CH2Cl2 (3x70 mL) and the combined 
organic solution washed with water (2x30 mL), brine (2x30 mL), dried with MgSO4, filtered, and the 
solvent removed under reduced pressure yielding 3.452 g of 52 (93%) as a white crystalline solid. 1H 
NMR (300 MHz, DMSO-d6) δ 7.50 (d, J = 1.9 Hz, 1H), 7.27 (dd, J = 8.4, 1.9 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 
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5.19 (t, J = 5.7 Hz, 1H), 4.42 (d, J = 5.6 Hz, 2H), 3.83 (s, 3H). LRMS (EI+)m/z 217 (M+, 33) 218 (M+1, 93), 219 
(M+2, 7.4), 216 (100), 215 (38) 213 (12), 201 (26), 199 (25), 189 (20), 187 (32), 172 (9.4), 157 (8.8), 137 
(50), 109 (37), 108 (74), 105 (15), 94 (29), 89 (15), 78 (22), 77 (52).  HPLC retention time 2.88 mins 
condition B. Absorbance spectra λmax 281 nm.  
 
4-methoxybenzylchloride(62). Thionyl chloride (430 µL, 6 mmol) was added to a solution of  61 (0.398 g, 
2.9 mmol)in 5 mL of CH2Cl2 in three equal portions over a period of 15 minutes. After allowing the 
solution to stir for 1 hour, the solvent was removed under reduced pressure yielding 0.464 g of 62 
(104%) as a clear oil. 1H NMR (300 MHz, CDCl3) δ 7.37 – 7.30 (m, 2H), 6.94 – 6.87 (m, 2H), 4.59 (s, 2H), 
3.83 (s, 3H). LRMS (EI+)m/z 156 (M+,17), 157 (M+1, 1.7), 158 (M+2, 5.4), 122 (9.2), 121 (100), 106 (2.3), 91 
(6.6), 77 (14).  
 
3-chloro-4-methoxybenzylchloride(53). Thionyl chloride (570 µL, 8 mmol) was added to a solution of 51 
(0.690 g, 4 mmol) in 5 mL of CH2Cl2 in three equal portions over a period of 15 minutes. After allowing 
the solution to stir for 1 hour, the solvent was removed under reduced pressure yielding 0.6362 g of 53 
(83%) as a white paste. 1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 2.1 Hz, 1H), 7.24 (dd, J = 8.4, 2.1 Hz, 1H), 
6.93 (d, J = 8.4 Hz, 1H), 4.63 (d, J = 5.3 Hz, 2H), 3.92 (s, 3H), 1.66 (t, J = 5.7 Hz, 1H). LRMS (EI+)m/z 190 
(M+,19), 191 (M+1, 1.9), 192 (M+2, 12), 193 (M+3, 1.2), 194 (M+4, 1.9), 157 (32), 156 (9.5), 155 (100), 112 
(5.4), 105 (8.6) 89 (4.7), 77 (22).   
 
3-bromo-4-methoxybenzylchloride(54). Thionyl chloride (3 mL, 42 mmol) was added to a solution of 52 
(3.431, 15.8 mmol) in 35 mL of dropwise over a period of 15 minutes. After allowing the solution to stir 
for 1 hour, the solvent was removed under reduced pressure yielding 3.50 g of 54 (100%) as a white 
solid. 1H NMR (300 MHz, DMSO-d6) δ 7.67 (d, J = 2.1 Hz, 1H), 7.44 (dd, J = 8.4, 2.1 Hz, 1H), 7.12 (d, J = 8.5 
Hz, 1H), 4.73 (s, 2H), 3.86 (s, 3H). ). LRMS (EI+)m/z 234 (M+,21.3), 236 (M+2, 28), 237 (M+3, 2.6), 238 
(M+4, 6.4), 221 (1.4), 202 (8.6), 201(97), 200 (11), 199 (100), 111 (2.2), 105 (17), 89 (11), 77 (34).  
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4-methoxybenzylcyanide(63).63 Sodium cyanide (0.162 g, 3.3 mmol) was ground with a mortar and 
pestle and added to a solution containing 62 (0.464 g, 3.0 mmol) in 10 mL of DMSO. The resulting 
solution was then heated in a 40 oC water bath for 1 hour, then allowed to stir over night. The solution 
was then poured into 25 mL of water, extracted into diethyl ether (3x50 mL), washed with brine (1x50 
mL), dried with MgSO4, and then the solvent removed under reduced pressure yielding 0.466 g of 63 
(107 %) as a clear oil. 1H NMR (300 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2H), 6.95 (d, J = 8.6 Hz, 2H), 3.94 (s, 
2H), 3.75 (s, 3H). HPLC retention time 3.19 mins condition B. Absorbance spectra λmax 225 nm minor λmax 
275 nm. LRMS (EI+)m/z 147 (M+,100), 148 (M+1, 10), 146 (45), 133 (3.3), 132 (38), 117 (8.6), 116 (21), 105 
(2.9), 91 (11), 77 (37).  
 
 
3-chloro-4-methoxybenzylcyanide(55).63 Sodium cyanide (0.188 g, 3.8 mmol) was ground with a mortar 
and pestle and added to a solution containing 53 (0.6362 g, 3.3 mmol) in 10 mL of DMSO. The resulting 
solution was then heated in a 40 oC water bath for 1 hour, then allowed to stir over night. The solution 
was then poured into 25 mL of water, extracted into diethyl ether (3x50 mL), washed with brine (1x50 
mL), dried with MgSO4, and then the solvent removed under reduced pressure yielding 0.542 g of 55 (90 
%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 7.58 (d, J = 2.1 Hz, 1H), 7.35 (dd, J = 8.5, 2.1 Hz, 1H), 
7.14 (d, J = 8.5 Hz, 1H), 3.97 (s, 2H), 3.85 (s, 3H). ). LRMS (EI+)m/z 181 (M+,52), 182 (M+1, 6.0), 183 (M+2, 
17), 184 (M+3, 1.6), 166 (9.2), 147 (10), 146 (100), 138 (8.4), 116 (4.9), 108 (7.6), 107 (33), 91 (4.8), 75 
(8.5). HPLC retention time 3.61 mins condition B. Absorbance spectra λmax 227 nm minor λmax 279 nm.    
 
3-bromo-4-methoxybenzylcyanide(56).63 Sodium cyanide (0.865 g, 17.6 mmol) was ground with a 
mortar and pestle and added to a solution containing 54 (3.491 g, 15.8 mmol) in 45 mL of DMSO. The 
resulting solution was then heated in a 40 oC water bath for 1 hour. The solution was then poured into 
150 mL of water, extracted into diethyl ether (3x150 mL), washed with brine (1x150 mL), dried with 
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MgSO4, and then the solvent removed under reduced pressure yielding 3.191 g of 56 (90 %) as a yellow. 
1H NMR (300 MHz, DMSO-d6) δ 7.58 (d, J = 2.1 Hz, 1H), 7.35 (dd, J = 8.5, 2.2 Hz, 1H), 7.14 (d, J = 8.5 Hz, 
1H), 3.96 (d, J = 10.4 Hz, 2H), 3.85 (s, 3H). LRMS (EI+)m/z 225 (M+,66), 226 (M+1, 9.0), 227 (M+2, 64), 228 
(M+3, 6.5), 212 (9.0), 210 (8.7), 182 (4.1), 147 (9.8), 146 (100), 130 (4.8), 116 (10), 103 (47), 89 (11), 76 
(14). HPLC retention time 3.74 mins condition B. Absorbance spectra λmax 227 nm minor λmax 280 nm.  
 
4-methoxyphenethylamine(64).63 5 mL of a 1 M borane THF solution was added to a flame dried reflux 
apparatus, that had previously been purged with N2. To this solution, a solution of 63 (0.361 g, 2.5 
mmol) in 5 mL of sieve dried THF was slowly added over 5 minutes, and the resulting solution was 
brought to reflux for 1.5 hours. The solution was then cooled to room temperature and quenched by the 
slow addition of 6 mL of methanol, then the solvent was removed under reduced pressure. The crude oil 
was then dissolved in 25 mL of 2 M HCl and washed with diethyl ether (2x25 mL), then the aqueous 
phased was basified to pH > 11 by the addition of 5 M NaOH, and extracted with CH2Cl2 (3x50 mL). The 
combined organic phase was then dried over MgSO4, filtered, and the solvent removed to yield the 
amine base as a clear oil. To this oil was added 10 mL of 48 % HBr in 5 mL of methanol, and the solvent 
removed under reduced pressure to yield 0.201 g of 64 (35 %) as an off white solid. 1H NMR (300 MHz, 
DMSO-d6) δ 7.14 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 3.81 (s, 3H), 2.95 (t, J = 6.8 Hz, 2H), 2.71 (t, J = 
6.8 Hz, 2H). HPLC retention time 1.80 mins condition B. Absorbance spectra λmax 223 nm minor λmax 275 
nm.    
 
3-chloro-4-methoxyphenethylamine(57).63 4.7 mL of a 1 M borane THF solution was added to a flame 
dried reflux apparatus, that had previously been purged with N2. To this solution, a solution of 55 (0.422 
g, 2.3 mmol) in 5 mL of sieve dried THF was slowly added over 5 minutes, and the resulting solution was 
brought to reflux for 1.5 hours. The solution was then cooled to room temperature and quenched by the 
slow addition of 8 mL of methanol, then the solvent was removed under reduced pressure. The crude oil 
was then dissolved in 25 mL of 2 M HCl and washed with diethyl ether (2x25 mL), then the aqueous 
phased was basified to pH 11 by the addition of 5 M NaOH, and extracted with CH2Cl2 (3x75 mL). The 
combined organic phase was then washed with brine (1x30 mL), dried over MgSO4, filtered and the 
solvent removed to yield the amine base as a clear oil. To this oil was added 5 mL of 48 % HBr in 10 mL 
of methanol, and the solvent removed under reduced pressure to yield 0.312 g of 57 (51 %) as a gray 
solid. 1H NMR (300 MHz, DMSO-d6) δ 7.75 (s, 3H), 7.36 (d, J = 2.0 Hz, 1H), 7.23 – 7.17 (m, 1H), 7.11 (d, J = 
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8.4 Hz, 1H), 3.84 (s, 3H), 3.09 – 2.96 (m, 2H), 2.80 (t, J = 7.6 Hz, 2H). ). HPLC retention time 2.17 mins 
condition B. Absorbance spectra λmax 279 nm.    
 
3-bromo-4-methoxyphenethylamine(58). 63 18 mL of a 1 M borane THF solution was added to a flame 
dried reflux apparatus, that had previously been purged with N2. To this solution, a solution of 56 (1.989 
g, 8.8 mmol) in 18 mL of sieve dried THF was slowly added over 5 minutes, and the resulting solution 
was brought to reflux for 1.5 hours. The solution was then cooled to room temperature and quenched 
by the slow addition of 20 mL of methanol, then the solvent was removed under reduced pressure. The 
crude oil was then dissolved in 50 mL of 2 M HCl and washed with diethyl ether (2x50 mL), then the 
aqueous phased was basified to pH 11 by the addition of 5 M NaOH, and extracted with CH2Cl2 (3x100 
mL). The combined organic phase was then dried over MgSO4, filtered and the solvent removed to yield 
the amine base as a yellow oil. To this oil was added 10 mL of 48 % HBr in 10 mL of methanol, and the 
solvent removed under reduced pressure to yield 2.352 g of 58 (88 %) as a gray solid. ). 1H NMR (300 
MHz, DMSO-d6) δ 7.71 (s, 3H), 7.50 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 
3.83 (s, 3H), 3.08 – 2.98 (m, 2H), 2.79 (t, J = 7.7 Hz, 2H). HPLC retention time 2.25 mins condition B. 
Absorbance spectra λmax 222 nm minor λmax 280 nm.  
 
 
4-hydroxyphenethylamine(tyramine)(65).63 A solution of 64 (0.200 g, 0.86 mmol) in 6 mL of 48% HBr 
was brought to reflux for 3.5 hours, after which it was allowed to cool to room temperature, diluted into 
5 mL of methanol, and the solvent was removed under reduced pressure yielding 0.127 g of 65 (91%) as 
a tan solid. 1H NMR (300 MHz, DMSO-d6) δ 9.31 (s, 1H), 7.71 (s, 3H), 7.04 (d, J = 8.4 Hz, 2H), 6.72 (d, J = 
8.4 Hz, 2H), 2.96 (s, 2H), 2.78 – 2.67 (m, 2H). ). HPLC retention time 1.30 mins condition B. Absorbance 
spectra λmax 221 nm minor λmax 275 nm. 
 
3-chloro-4-hydroxyphenethylamine(3-chloro-tyramine)(49).63 A solution of 57 (0.318 g, 1.3 mmol) in 9 
mL of 48% HBr was brought to reflux for 3.5 hours, after which it was allowed to cool to room 
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temperature, diluted into 5 mL of methanol, and the solvent was removed under reduced pressure 
yielding 0.285 g of 49 (88 %) as a tan solid. 1H NMR (300 MHz, DMSO-d6) δ 10.07 (s, 1H), 7.71 (s, 3H), 
7.25 (d, J = 1.8 Hz, 1H), 7.06 – 6.98 (m, 1H), 6.92 (d, J = 8.3 Hz, 1H), 2.99 (s, 2H), 2.74 (t, J = 7.6 Hz, 2H). ). 
HPLC retention time 1.55 mins condition B. Absorbance spectra λmax 220 nm minor λmax 280 nm.  
 
3-Bromo-4-hydroxyphenethylamine(3-bromo-tyramine)(50).63 A solution of 58 (1.686 g, 5.4 mmol) in 35 
mL of 48% HBr was brought to reflux for 3.5 hours, after which it was allowed to cool to room 
temperature, diluted into 10 mL of methanol, and the solvent was removed under reduced pressure 
yielding 0.285 g of 50 (88 %) as an impure brown solid. An attempt to purify the crude solid through 
column chromatography (0-10 % Methanol and 3 % triethylamine in DCM) yielded a black impure oil.  
Feeding experiments for HPAA and norcoclaurine analogues. A 0.2 mM solution of halogenated 
tyrosine (either chloro, bromo, or iodo) in 10 mM phosphate buffer was warmed to 37 oC and converted 
into the corresponding HPAA or norcoclaurine as described above. The resulting analogues in phosphate 
solution was then diluted into an equal volume of 2x Gamborg's media and filter sterilized through a 
0.22 µm filter. Berberis cells were then shaken in this solution at room temperature. After a period of 1 
week, the solids were separated from the liquid via gravity filtration, then lyophilized and stored at -80 
oC until they were ready for analysis.  
General Procedure for the Evaluation of background reaction rates for Pictet-Spengler reactions. 0.5 
mM of HPAA and dopamine were mixed in a solution of each respective buffer. The rate of background 
reaction was determined using HPLC (condition C) by monitoring the area of the resulting norcoclaurine 
peak at 225 nm. The resulting areas were then plotted as a function of time to yield straight lines. The 
slopes of these lines were taken to be the rate of background reactions.   
General Procedure for Norcoclaurine synthase kinetic assays. Sequential 1:1 dilutions of HPAA (or 
dopamine), were made so that 8 different concentrations of the substrate were prepared on a log2 
scale. These were then reacted in the presence of a constant concentration of dopamine (or HPAA), 
buffer (50 mM TRIS, 25 mM imidazole,25 or 100 mM HEPES, 25 mM maleic acid), and enzyme (8 µg/mL). 
The reaction was quenched at different time points by adding either 80 µL of the reaction into 120 µL of 
methanol or 80 µL of reaction into 20 µL of 1 M HCl. The rate of the reaction was determined using HPLC 
(condition C) by monitoring the area of the resulting norcoclaurine peak at 225 nm. The resulting areas 
were then plotted as a function of time to yield straight lines, the slopes of which gave the rates in terms 
of µV*s /s. These rates were then plotted against the concentration of the varied substrate (either HPAA 
or dopamine), and the resulting curves were fit to the Michaelis-Menten equation (Eq. 3.1), using 
OriginPro8 (Origin Lab).   
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General Procedure for the Evaluation of buffers concentrations on activity of Norcoclaurine synthase. 
Solutions containing 1 mM HPAA and Dopamine were reacted in the presence of a constant 
concentration of enzyme (8 µg/mL) and differing concentrations of buffer (20-100 mM). The rate of the 
reaction was determined using HPLC (condition C) by monitoring the area of the resulting norcoclaurine 
peak at 225 nm. The resulting areas were then plotted as a function of time to yield straight lines, the 
slopes of which gave the rates in terms of µV*s/s. These rates were then plotted against the 
concentration of the varied buffer to determine if the buffer affected the rate of catalysis.  
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